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ABSTRACT
HYPOXIA-REGULATED EXPRESSION OF GLUT1 IN GBM CELL LINES
By
Marissa Kane

Unlike normal cells, cancer cells can grow in low oxygen (hypoxic) environments.
Changes in relative oxygen concentration can alter gene expression in tumors to allow for
their selective growth. The result of such changes allows the tumor to adapt its cellular
metabolism and promote tumor progression. Most notably, hypoxic conditions induce
expression of the transcription factor hypoxia inducible factor 1 (HIF-1). HIF-1 is thought
to directly affect glucose transporter 1 (GLUT1) expression levels in hypoxic conditions.
This study sought to determine the relationship between HIF-1 and GLUT1 expression
levels within normoxic and hypoxic environments utilizing an in-vitro GBM model. The data
accumulated in this study determined that hypoxia correlates with relative expression
levels of hypoxia inducible factors (HIFs) as well as GLUT1. HIF-1 and GLUT1 appear to
have different expression levels in fibroblast cells than in GBM cells, solidifying that HIF-1
and GLUT1 are suitable targets for future GBM treatments.

ii

Copyright by
Marissa Kane
2018

iii

ACKNOWLEDGEMENTS

I would first like to thank my thesis advisor Dr. Robert Belton Jr. of Northern Michigan
University. In addition to the intellectual and personal guidance he provided me during my
undergraduate years, he has become a second voice in my head throughout my graduate
education. I would be remiss without thanking him for shaping me into the student and
mostly independent researcher I am today. I would also like to thank Dr. John Lawrence,
PhD of the Upper Michigan Brain Tumor Center. His perpetual leadership and support on
my project as well as for the general research projects in the UMBTC was always a blessing.
I would especially like to thank him for reigning me in during my constant attempts to
expand my thesis project.
I would also like to thank Dr. Robert Winn, PhD for being a positive, critical teacher in GBM
biology. His guidance at the Thursday morning meetings over the last five years has
coached me into being critical over published works and to take things with a grain of salt. I
would also like to thank him for formally serving on my thesis committee.
I would also like to thank Dr. Sonia Geschwindt, MD for her guidance as a concurrent premedical student in this research program. Her advice and generosity in allowing me to
shadow her in clinic and in the operating room gave me renewed inspiration for becoming
a woman in science as well as in medicine. I would also like to thank her for serving on my
thesis committee as well.
I would also like to thank Dr. Josh Sharp, PhD for being a positive force during my research
and academic career at NMU. I would also like to thank him for serving on my thesis
committee.
I would like to thank some of my lab-mates: Nick Shortreed, Melanie Flaherty, Dustin
Degrave, and Chris McMann for their ready opinions, help with PCR, and friendship. I could
not have done this project without any of you. I would also like to thank my other labmates: Erik Peterson, Aaron Mellesmoen, Colin Smith, and Amanda Wigand for their
guidance, support, and friendship throughout my graduate career. I would also like to
thank my friends: Danielle Brogren, Carol Kessel, Amanda Vanderplow, Niyomi House,
Luke VanOsdol, Travis Moe, and Claire Smith.
Finally, I would like to thank those who provided a never-ending stream of encouragement
during my education: my parents, my grandparents, my sister and brother, aunts and
uncles, and my wonderful boyfriend. You all renewed my inspiration to continue during
the many tough times over the last three years. This research was not possible without
your constant love and support.
This thesis follows the format specified by the NMU Department of Biology and the CBE
Style Manual.

iv

Table of Contents

List of Figures………………………………………………………………………..…………………………………..vii
List of Tables……………………………………………………………………………………………………………...viii
List of Symbols and Abbreviations……………………………………………………………………………......ix
Introduction...................................................................……………………………………………………….……......1
Introduction of Glioblastoma (GBM)…………………………………………………….......1
Hypoxia and the Tumor Microenvironment……………………….…………………......4
Introduction to the Warburg Effect…………………………………………………....…......8
Tissue Distribution of Hypoxia Inducible Factors (HIFs)………………………….11
Induction and Regulation of Hypoxia Inducible Factors (HIFs) 1 and 2…....13
Induction and Regulation of Hypoxia Inducible Factor 3……………………........18
Target Genes Downstream of HIFs …………………………………………………….......20
Angiogenesis……………………………………………………………………………....20
Metabolic Remodeling………………………………………………………………...22
Glucose Transporters……………………………………………………………….....25
Summary………………………………………………………………………………………………………....27
Literature Review Figures………………………………………………………………………………...29
Objectives and Hypotheses.......................………………………………………………………………………....36
Methods……….......................………………………………………………………………………………………..…...38
PCR Primer Design………………………………………………………………………………...38
Cell Culture. ……………………………………………………………………………………….…38
Hypoxia Time Course Assay: Cell Culture Design…………………………………….40
Hypoxia Time Course Assay: Direct Cell Lysis………………………………………....41
RNA Isolation and First Strand cDNA Synthesis………………………………………41
End-Point Polymerase Chain Reaction (EP-PCR)....………..…….…………………..42
Real-Time (Quantitative) Polymerase Chain Reaction (qPCR)...........................43
Statistical Analysis……………………………………………………………...................…......45
v

Limitations of Study………………………………………………………………......................47
Results.........................……………………………………………………………….....................................................49
Discussion.......................………………………………………………………...........................................................80
General Effects of Cell Line and Hypoxic Exposure Treatment on Lumped Expression
of HIF-1, HIF-1, and GLUT1.........................................................................................................83
Specific Effects of Cell Line and Hypoxic Exposure Treatment on Gene
Expression................................................................................................................................................84
Effect of Cell Type on Individual Genes Expressed..................................................84
Effect of Hypoxia Exposure Treatment on Individual Genes Expressed........85
Interaction Effect of Cell Type and Hypoxia Exposure Treatment on Individual Genes
Expressed..................................................................................................................................................87
Potential Effect of Chronic versus Acute Hypoxia...................................................................87
Summary...................................................................................................................................................88
Future Studies........... .............................................................................................................................90
Resource Availability……………………………………………………................................................................91
References.....…………………………………………………....................................................................................92
Appendix: Protocols for RNA Isolation, First Strand cDNA Synthesis and qPCR................103

vi

List of Figures

Figure 1: Spatial relationship between a blood vessel, hypoxia, and tumor microenvironment.............................................................................................................................................................29
Figure 2: Domain structures of HIF transcription factors....................................................................30
Figure 3: HIF-/ hetero-dimerization and DNA Binding...................................................................31
Figure 4: The Warburg Effect ...........................................................................................................................32
Figure 5: Mechanisms of Hypoxia Inducible Factor 1 (HIF-1) Stabilization..............................33
Figure 6: Expression of the genes HIF-1 and HIF-1 was confirmed in both hypoxia
treated U87MGMG cells as well as in U87MG cells that only grew in a normoxic
environment.............................................................................................................................................................60
Figure 7: Expression of the genes HIF-2 and HIF-2 was confirmed in both hypoxia
treated U87MG cells as well as in U87MG cells that only grew in a normoxic
environment.............................................................................................................................................................61
Figure 8: Gel Image depicting confirmed expression of the genes HIF-3 and GLUT1 in both
hypoxia treated U87MG cells as well as in U87MG cells that only grew in a normoxic
environment. ...........................................................................................................................................................62
Figure 9: Gel Image depicting confirmed expression of GLUT3 in both hypoxia treated
U87MG cells as well as in U87MG cells that only grew in a normoxic environment................63
Figure 10: Bar graph depicting relative expression level of HIF-1 in U87MG cells................64
Figure 11: Bar graph depicting relative expression levels of HIF-1 in U87MG cells..............66
Figure 12: Bar graph depicting relative expression levels of GLUT1 in U87MG cells..............67
Figure 13: Bar graph depicting relative expression levels of HIF-1α, HIF-1, or GLUT1 in
MSU1.1 cells after hypoxic exposure treatment.......................................................................................68
Figure 14: Plot of Multivariate Analysis Estimated Marginal Means depicting the
interaction between hypoxia treatment, cell line, and HIF-1α relative expression..................77
Figure 15: Plot of Multivariate Analysis Estimated Marginal Means depicting the interaction
between hypoxia treatment, cell line, and HIF-1 relative expression..........................................78

vii

Figure 16: Plot of Multivariate Estimated Marginal Means depicting the interaction
between hypoxia treatment, cell line, and GLUT1 relative expression..........................................79
List of Tables

Table 1: HIF-1 Targets That Regulate Glucose Metabolism.................................................................35
Table 2: PCR Primer Sequences.......................................................................................................................48
Table 3: Summary of End-Point PCR Study Results................................................................................65
Table 4: Delta CT Values Used for MANOVA Multivariate Analysis.................................................69
Table 5: MANOVA Tests of Between-Subjects Effects............................................................................70
Table 6: Test of Between-Subjects Effects Shown for Each Gene of Interest...............................71
Table 7: Pairwise Comparisons of Various Time Points in Hypoxic Environment and Effects
Seen in The Expression of HIF-1α Conducted by Multiple Univariate ANOVA...........................72
Table 8: Pairwise Comparisons of the Expression Levels of HIF-1 at Each Hypoxia Time
Point Conducted by Multiple Univariate ANOVA analysis....................................................................73
Table 9: Pairwise Comparisons of the Expression Levels of GLUT1 at Each Hypoxia Time
Point Conducted by Multiple Univariate ANOVA analysis....................................................................74
Table 10: Multiple univariate anova pairwise comparisons of expression levels of HIF-1,
HIF-1 and glut1 in U87MG cells and MSU1.1 cell lines........................................................................75
Table 11: Estimated marginal means of HIF-1α, HIF-1, and GLUT1 in both U87MG and
MSU1.1 Cell Lines...................................................................................................................................................76

viii

List of Symbols and Abbreviations

BBB: Blood Brain Barrier
CSC: Cancer Stem Cells
CT: Cycling Threshold
EP-PCR: End-Point Polymerase Chain Reaction
GBM: Glioblastoma Multiforme
GLUT1: Glucose Transporter 1
GSC: Glioma Stem Cell
HIF: Hypoxia Inducible Factor
MCT: Monocarboxylate Transporter
MGMT: O6-methylguanine–DNA methyltransferase
mRNA: Messenger Ribonucleic Nucleic Acid
qPCR: Quantitative Real-Time Polymerase Chain Reaction
TMZ: Temozolomide
VEGF: Vascular Endothelial Growth Factor

ix

Introduction

Introduction to Glioblastoma (GBM)

The current standard of care for Glioblastoma multiforme tumors (GBM) rarely
cures the patient. The typical survival time for 75% of patients is 18 months after their
diagnosis and less than 10% of patients survive longer than 5 years past diagnosis, despite
severe surgical debulking procedures, chemotherapy, and radiation treatment regimens
(Mansour, Fields, Macomson, & Rixe, 2014)(Ali, 2013).
This low survival rate is mostly due to the ability of these tumors to recur quickly
and aggressively. It is thought that within the tumor there are distinct subpopulations of
cells that are stem-like in their behavior (Singh et al., 2003). These stem-like cells give the
tumor self-renewing properties and therefore help the tumor to grow back from only a few
cells remaining after treatment (Hjelmeland et al., 2011, p. 829). GBMs are typically hard
to surgically remove because the bulk of the tumor can be diffuse and often lies adjacent to
important fiber tracts, blood vessels, and other structures in the brain (Park et al., 2010).
Debulking surgeries reduce the size of the bulk tumor but fail to target specific
subpopulations of cells within the tumor, such as the stem-like cells that can help the tumor
grow back. The location of the tumor and the inherent cellular and genetic heterogeneity
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within the tumor can influence how aggressive the surgeon will be when removing the
tumor (Y. Wang & Jiang, 2013).
In addition to surgery, also included in the standard of care regimen are radiation
and chemotherapy. Surgery targets the bulk of the GBM, but leaves behind as much of the
tumor as is needed to preserve as much brain function as possible (Park et al., 2010).
Radiation and chemotherapy specifically target fast-growing cells that inherently comprise
the bulk of the tumor mass, but these treatments have variable effectiveness because they
fail to target the characteristic hypoxic microenvironment within the tumor. The hypoxic
tumor microenvironment promotes tumor aggression and stem cell formation and confers
treatment resistance (Covello et al., 2006). These methods are inherently not effective at
killing the slow growing cells in the GBM and therefore are leaving the cancerous stem-like
cell population mostly unharmed. However, all stem cells can’t just be targeted to kill the
GSCs, as there is the issue of having undesired effects by killing healthy neural stem cells in
addition to the malignant stem cells which would further impair the healing process
(Lawson et al., 2007).
The cellular, genetic, and epigenetic heterogeneity of GBMs makes designing
targeted treatments difficult. One example of a mutation present in some GBM patients in
in the enzyme IDH1 (isocitrate dehydrogenase 1). IDH1 is a mitochondrial enzyme that,
when mutated, has a normal loss in function and leads to the accumulation of 2hydroxyglutarate (2-HG) (Turkalp, Karamchandani, & Das, 2014) which has been shown to
inhibit the enzymatic function of several histone and DNA demethylases. This leads to
uncorrected methylation on genes whose expression, when altered, can confer
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tumorigenesis (Xiang & Zhi-Qiang, 2015). So indirectly, IDH1 accumulation confers tumor
aggression and its expression is characteristic in secondary GBM. IDH1 acts as a prognostic
marker in GBM (Parsons et al., 2008) since its expression correlates with tumor grade
(Kickingereder et al., 2015). Overall, patients have genetic or epigenetic mutations in
combinations that are often unique to their tumor, and often these mutations prevent
treatments such as chemotherapy, radiation, or surgery from curing the patient.
Consequently, there is a need for individualized treatments based on the patient’s tumor
genetic profile.
In addition to genetic mutations present in GBMs, epigenetic changes are also
prevalent and preclude certain chemotherapy treatments from eradicating the tumor.
Epigenetic changes are evident by methylation or demethylation of promoter or enhancer
regions of DNA, which can lead to gene overexpression or gene silencing. An example of
this is in the gene MGMT (O6-methylguanine–DNA methyltransferase). The MGMT gene
codes for a DNA repair protein that removes alkyl groups that chemotherapy drugs, such as
Temozolomide (TMZ), add to tumor DNA to kill cells (Esteller et al., 2000). The alkyl
groups that TMZ adds to the tumor DNA, halts cell replication followed by apoptosis in the
affected cell (Hegi et al., 2004)(Ochs & Kaina, 2000)(L. Liu, Markowitz, & Gerson, 1996).
The potential effects of TMZ on the tumor DNA of a person with normal MGMT will be
unaffected by the chemotherapy drug because their functional MGMT protein will just fix
the DNA alkylation that the TMZ caused. Therefore, when the MGMT promoter is
methylated and its expression is silenced, the tumor becomes more susceptible to
chemotherapy alkylating drugs, such as TMZ, and when combined with radiotherapy leads
to longer overall survival for the patient (Hegi et al., 2005). Therefore, the gene MGMT is a
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common prognostic factor that surgeons and oncologists use to design treatments that will
be as effective as possible for the patient (Hegi et al., 2005).
In addition to the challenges presented by the cellular, genetic, and epigenetic
heterogeneity of the tumor, aspects of the general biology of the brain leads to challenges,
specifically the blood brain barrier. The presence of the blood brain barrier (BBB) makes it
difficult to treat GBM, as it severely limits what can pass into the brain. The BBB is a
neuroprotective barrier system for the capillaries of the brain and is mostly comprised of
endothelial cells connected by tight junctions (Persidsky, Ramirez, Haorah, & Kanmogne,
2006) and acts to prevent toxins and pathogens from reaching the brain. Because of the
challenges in permeating the BBB, drug design is difficult and existing treatments for other
cancers might not be a viable option for a GBM patient (Juillerat-Jeanneret, 2008).
However, nanotechnology appears to be growing more effective at treating GBM by
exploiting the presence of LDL receptors on the endothelial cells (Dehouck, Dehouck,
Fruchart, & Cecchelli, 1994) and are also more highly expressed in GBM (Nikanjam, Gibbs,
Hunt, Budinger, & Forte, 2007).

Hypoxia and the Tumor Microenvironment

Abnormal physiology and abnormal location of cells contribute to the characteristic
uncontrolled growth of cancer. The cancer cells proliferate with very few stop mechanisms
and turn off remaining genes that, when normally translated to proteins, would act to
prevent abnormal cell growth. Resulting from the constant growth is an increased
4

metabolism (discussed more below) and a growing distance between cancer cells and
proper vasculature. Although cancer cells are abnormal in terms of their growth,
metabolism, and other properties, they have need to maintain some semblance of normal
cell physiology, including proper nutrient delivery and waste management. Although the
cancer cells try to mimic some of the normal physiological processes such as angiogenesis
(blood vessel formation), this ultimately fails and there is still variably lower oxygen in
many parts of the tumor, usually in a gradient-like manner. Consequently, the typical
microenvironment of bulk tumors is generally hypoxic (lower than normal oxygen), low
pH, and nutrient deficient (Pouysségur, Dayan, & Mazure, 2006)(Pouysségur, Dayan, &
Mazure, 2006) since they don’t have proper vasculature.
Cancer cells have the unique ability to survive under hypoxic conditions (Hsu &
Sabatini, 2008). Hypoxia has been characterized as a main reason for the poor prognosis
for GBM patients (G. L. Semenza, 2002) and has been implicated in tumor cell proliferation,
survival, cell migration, invasion, and treatment resistance (G. L. Semenza, 2002)(Bar, Lin,
Mahairaki, Matsui, & Eberhart, 2010)(Joseph et al., 2015). Hypoxic conditions have been
shown to induce changes in a myriad of genes, which lead to numerous new physiological
changes that distinguish cancer from normal tissue. Resulting from the hypoxic
microenvironment itself, and the genetic changes indirectly elicited by hypoxia, treatments
are largely ineffective for GBMs (P. Wang et al., 2017, p. 1)(Mohyeldin, Garzon-Muvdi, &
Quinones-Hinojosa, 2010)(Chiche, Ricci, & Pouysségur, 2013)(Chiche, Ricci, & Pouysségur,
2013). Some of the characteristic aggressiveness of GBMs derives from the heterogeneity of
the cells within the tumor, as well as from genetic and epigenetic changes (Liberti &
Locasale, 2016a).
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A subpopulation of cells in GBM tumors, cancerous glioma stem cells, (GSCs) share
the self-renewing properties of normal stem cells, but the malignancy and aberrant
signaling of cancer cells (Singh et al., 2003)(Qiu, Fang, Luo, & Ouyang, 2015). These tumorinitiating cells or cancer stem cells (CSCs) exist within the tumor and provide it with the
ability to resist treatment and to lie dormant until the cancer stem cells eventually
recapitulate the tumor. CSCs might originate from non-stem cancer cells that
dedifferentiate due to hypoxic conditions within the tumor microenvironment (P. Wang et
al., 2017). The alleged CSCs or tumor-initiating cells have displayed the ability to
recapitulate a tumor, despite only comprising a small percentage of the overall tumor mass
(P. Wang et al., 2017)(Singh et al., 2003). A recent study found that the glioma stem cell
(GSC) subpopulation led to tumor aggressiveness, but also that GSCs are dedifferentiated
from differentiated glioma cells (P. Wang et al., 2017). This highlights the debate about the
origin of GSCs, whether they derive from malignant neural stem cells or whether they are
differentiated glioblastoma cells that dedifferentiated into GSCs.
Both cancer stem cells and genetic variety within the tumor are implicated in the
scheme of tumor development (Liberti & Locasale, 2016b). The tumor microenvironment
selects for the growth of different cell populations within GBMs, however, it seems intuitive
that the opposite is true as well. The heterogeneity comprising the GBM microenvironment
results in different growing conditions for cells and leads to genotypic and phenotypic
variability within the tumor, which then leads to difficulties in making targeted GBM
treatments (Covello et al., 2006)(Lawson et al., 2007)(Hegi et al., 2005)(Gao, Shen, Jin,
Miao, & Qiu, 2016). Overall, there appears to be a relationship between the types of cells
comprising these GBM subpopulations, the relative oxygen conditions and the vascularity
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of the tumor microenvironment, which is discussed more in-depth in future sections. In
addition to the advantages directly conferred to cancer stem cells by hypoxia, there are
numerous hypoxia induced downstream changes that elicit genetic changes within GBMs
that confer other advantages for the tumor (Liberti & Locasale, 2016b). These genetic
changes within the tumor are the foundation for the characteristic ‘hallmark’ changes seen
in cancer progression: such as angiogenesis, immune evasion, resistance to apoptosis,
dormancy from cancer stem cells, inflammation, metastasis, resistance to therapies, and
metabolic reprogramming (Hanahan & Weinberg, 2011)(Ravi et al., 2002), which are
discussed again below. As described above, epigenetic changes within tumors also confer
different factors that affect the prognosis of the patient (Hegi et al., 2005).
Due to the perpetual and uncontrolled growth of cancer cells, tumors quickly
outgrow their available vascular supply. As tumors grow, proper vasculature is not created
quickly enough to adequately provide for the metabolic needs of the tumor cells; most
notably, oxygen delivery. Oxygen must diffuse over long distances to reach the portions of
the tumor that lies farthest from the vascular supply. This mismatch of O2 consumption
and delivery in certain areas of the tumor leads to a gradient of local decreased partial
pressure of oxygen, which is referred to as hypoxia (Denko, 2008). Hypoxia is the relative
deprivation of oxygen and a complete deprivation is called anoxia (West, 1977). Hypoxia
has been shown to lead to the expression of genes that lead to some of the ‘hallmark’
changes seen in cancer, including: sustained proliferative signaling, evasion of growth
suppressors, activation of invasion and metastasis mechanisms, replicative immortality,
induction of angiogenesis, and resistance to cell death (Heikkilä, Pasanen, Kivirikko, &
Myllyharju, 2011)(Heikkilä, Pasanen, Kivirikko, & Myllyharju, 2011). There are also several
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‘emerging hallmarks’ or major themes underlying cancer progression that are now being
studied: reprogramming energy metabolism and evasion of immune destruction (Hanahan
& Weinberg, 2011)(Ravi et al., 2002).
Cancer cells, like normal cells, require nutrients and mechanisms to transport
wastes. To accommodate the needs of the growing tumor, cancer cells can initiate the
process of angiogenesis to create new blood vessels (Hanahan & Weinberg, 2011).
However, blood vessel formation in cancer is very different from normal vessel formation.
Normal physiological processes, such as in embryogenesis, wound healing, or female
reproductive cycling, characteristically have new blood vessel formation. Angiogenesis is
the short-lived process of forming new vessels in developing and normal tissues; the
vessels are organized and lined with endothelial cells without gaps between them (Ferrara,
2010). In contrast, tumor neovasculature is aberrant and is accentuated in hypoxia
(Ferrara, 2010)(Hanahan & Weinberg, 2011) and this can also lead to uneven drug
distribution when drugs even make it this far into the tumor. The process of cancerinduced angiogenesis is discussed more in depth in later sections.

Introduction to the Warburg Effect

As mentioned above, angiogenesis occurs in the tumor to attempt to fulfill the vast
metabolic demand of the proliferating cancer cells. However, the process does not succeed
at fully oxygenating the tumor and this causes changes in the relative oxygen concentration
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in the tumor microenvironment. Normal tissues anaerobically process glucose to pyruvate
using glycolysis in the cytosol before further breakdown to carbon dioxide in the
mitochondria, which creates 36 ATP from each glucose molecule in the aerobic process
called oxidative phosphorylation (Warburg & others, 1956a). Normally, glycolysis is not
the primary process used for the bulk of energy metabolism, as it is far less energy efficient
than normal mitochondrial oxidative phosphorylation. Overall, glycolysis in the cytoplasm
accounts for only about 10% of the ATP generation needed for a normal cell, with the other
90% being generated from pyruvate processed by oxidative phosphorylation in the
mitochondria of the cell (DeBerardinis et al., 2007).
Despite the greater metabolic need of actively proliferating cancer cell
subpopulations, nearly 50% of a cancer cell’s energy is produced by glycolysis (Denko,
2008). Cancer cells preferentially use glycolysis followed by lactic acid fermentation in the
cytosol, despite its inefficiency at creating ATP per glucose molecule: which is reportedly
~18-fold less efficient at making ATP than is mitochondrial oxidative phosphorylation
(Denko, 2008). In the 1920s, Otto Warburg characterized this phenomenon and termed it
aerobic glycolysis, which is now also referred to as the Warburg Effect (Warburg & others,
1956b)(Hsu & Sabatini, 2008)(Warburg, Wein House, Burk, & Schade, 1956). The inner
workings of the Warburg Effect remain elusive in cancer cell metabolism studies today, but
there seems to be a consensus that this metabolic shift to glycolysis is advantageous to the
tumor. In 1929, Crabtree confirmed Warburg’s findings of ‘aerobic glycolysis’, but also
found fermentation occurring. Warburg later proposed that dysfunctional mitochondria
were to blame, but his theory was not very popular until signaling cascades were better
understood, as many of the enzymes used in mitochondrial metabolic processes are
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downregulated by hypoxia induced signaling changes (Denko, 2008)(Papandreou, Cairns,
Fontana, Lim, & Denko, 2006). Accordingly, some experts believe that both mitochondria
and aberrant aerobic glycolysis play a role in Warburg’s phenomenon. Although aerobic
glycolysis in the cytosol is less efficient at generating ATP per molecule of glucose than
oxidative phosphorylation in the mitochondria, lactate production derived from glucose
metabolism occurs 10-100 times faster than glucose oxidation via the mitochondria (Figure
4) (Vander Heiden, 2009)(Shestov et al., 2014). This difference in the speed of glucose
breakdown and subsequent rapid ATP production could account for why aerobic glycolysis
is used preferentially to mitochondrial oxidative phosphorylation.
Many of the genetic and phenotypic changes described by the Warburg Effect can be
attributed to the hypoxic conditions that occur within the tumor microenvironment,
specifically by the family of transcription factors called hypoxia-inducible factors (HIFs)
(Figures 1) (Ruan, Song, & Ouyang, 2009)(Hsu & Sabatini, 2008). Hypoxia leads to induced
expression of HIFs, which have many downstream target genes: most notably, VEGF and
GLUT1 (Fukumura et al., 2001). Glucose transporter 1 (GLUT1) facilitates the uptake of
glucose into cells and is overexpressed in GBMs. GLUT1 overexpression allows for higher
rates of aerobic glycolysis which indirectly creates an acidic tumor microenvironment
(Liberti & Locasale, 2016b) due to the excess of lactate from fermentation (Figure 4).
However, this pH drop is short-lived because monocarboxylate transporter (MCTs)
expression increases to transport the lactate out of the cell. However, the lactate does not
all leave the cell despite the addition of more MCTs; not all the lactate can be transported
away from the cell due to the poor vasculature constructed via tumor induced angiogenesis
(Gillies, Robey, & Gatenby, 2008)(Newell, Franchi, Pouyssegur, & Tannock, 1993).
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Regardless, this decrease in pH confers advantages to the tumor, such as increasing
VEGF expression (Fukumura et al., 2001), the main driver of angiogenesis: a process that
facilitates more opportunities for the delivery of oxygen and other nutrients, as well as
waste removal. Additionally, new vasculature creates a way for cancer cells to get
transported to other areas of the body, which drives tumor invasion and metastasis (Sun et
al., 2007). The preference for quick glucose metabolism, rather than more efficient
metabolism, results in competition for resources between tumor cells and other cells in the
vicinity such as tumor-infiltrating lymphocytes and stromal cells (Chang et al., 2015)(Ho et
al., 2015). Therefore, hypoxia and the induced expression of hypoxia inducible factors play
an important role in regulating aerobic glycolysis and thus GLUT1 expression in tumor
cells.

Tissue Distribution of Hypoxia Inducible Factors (HIFs)

Hypoxia inducible factors are a family of transcription factors that respond to
relative changes in oxygen or in response to oncogenic signaling mechanisms (Smith,
Robbins, & Ratcliffe, 2008)(Wilkins, Abboud, Hancock, & Schofield, 2016)(Y. Liu et al.,
2009a, p. -3). Three paralogs of the hypoxia-inducible transcription factor family have
been identified in mammals: HIFs-1, 2, and 3 (Figure 2) (Tanaka, Wiesener, Bernhardt,
Eckardt, & Warnecke, 2009). HIFs are a heterodimeric transcription factors that possess
either HIF-1 or HIF-2 as the oxygen sensitive subunit and a constitutively expressed HIF
beta subunit (Figure 3) (Denko, 2008). The expression of both HIF-1 and HIF-2 have been
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implicated in several normal physiological processes such as erythropoiesis and
angiogenesis (C.-L. Chen, Chu, Su, Huang, & Lee, 2010, p. 57). The HIF-1α subunit is
ubiquitously expressed throughout the body, although two groups did not detect HIF-1
expression in normal brain tissues (Zhong et al., 1999)(Y. Liu et al., 2009a). However, it
should be noted that HIF-1 expression is correlated to pathological grade of glioma (Ravi
et al., 2002). HIF-1 is stabilized and upregulated in hypoxic conditions, after oncogene
activation, and/or from tumor suppressor gene inactivation, which leads to downstream
gene activation (Figure 5). Loss of function of the tumor suppressor gene p53 upregulates
HIF-1 expression (Ravi et al., 2002). Expectedly, higher expression levels of HIF-1 and
VEGF were seen in the most necrotic and least vascularized areas of the GBM (Chan et al.,
1998). The correlation with HIF-1, VEGF, and GBM pathological grade indicates that HIF1 is likely important in regulating invasion and metastasis.
In normal tissues, HIF-2α plays a role in the process of erythropoiesis. Generally, the
main actions of HIF-1 or HIF-2 are to mediate the cellular and systemic responses to
hypoxic conditions in the body, but the expression of each HIF has yet to be fully elucidated
(Patel & Simon, 2008). HIF-2α is expressed in certain tissues: vascular endothelial cells,
neural crest cell derivatives, glial cells (Hu et al., 2006), lung type II pneumocytes (Patel &
Simon, 2008), liver parenchyma, cardiomyocytes, and interstitial cells in the kidney and
several other organs (Ruan et al., 2009)(Zhao, Du, Shen, Zheng, & Xu, 2015)(M. S. Wiesener
et al., 1998)(M. Wiesener, 2003), neuroblastoma (Holmquist-Mengelbier et al., 2006), and
glioma stem cells (Li et al., 2009). HIF-2α expression has been implicated with several
types of stem cells , including embryonic stem cells (Covello et al., 2006, p. -4)(Hu et al.,
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2006)(Mohyeldin et al., 2010). Importantly, HIF-2 makes an ideal therapeutic target
because GSCs overexpress HIF-2 whereas and normal neural progenitor cells produce
nearly undetectable levels (Li et al., 2009). Therefore, since HIF-2 isn’t produced in
healthy progenitor cells, it seems likely that a therapy aimed at targeting HIF-2 is a viable
option. By somehow blocking the expression of genes downstream of HIF-2, a cancer
specific therapy could be made that would potentially have less unwanted cell death and
therefore fewer unwanted effects for patients. Contrastingly, since HIF-1 is more
ubiquitously expressed, it might not be the most suitable HIF available to target only GBM
and GSCs because it might cause undesired cell death in other tissues. A third HIF 
isoform, HIF-3α, was discovered in 1998; HIF-3α expression is poorly characterized and
the role that HIF-3α plays in hypoxia mediated functions is poorly understood. Overall, less
is known about HIF-3 expression and regulation than about HIF-1 and HIF-2 (Tanaka
et al., 2009).

Induction and Regulation of HIF -1 and HIF-2

HIF-1
The hypoxia inducible factor proteins HIF-1α and HIF-2α share very similar protein
domains (Figure 2) and are mainly regulated via their oxygen-dependent domains (ODDs).
Their shared homology is most apparent in the N-terminal basic Helix-Loop-Helix (bHLH)
domain which is adjacent to the two Per-ARNT-Sim (PAS) domains: the oxygen-dependent
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domains characteristic of HIF-1 and HIF-2. Under hypoxic conditions, the PAS domains
allow hetero-dimerization and DNA binding to occur; the C-terminal of HIF facilitates
interactions with coactivators such as CREB binding protein and p300 (Jiang, Zheng, Leung,
Roe, & Semenza, 1997)(Kallio et al., 1998)(Pugh, O’Rourke, Nagao, Gleadle, & Ratcliffe,
1997)(Pugh, O’Rourke, Nagao, Gleadle, & Ratcliffe, 1997). These coactivators facilitate
transcription by interacting with sequence specific DNA binding proteins and with other
RNA Polymerase II associated general transcription factors (G. Semenza, 2000).
Importantly, there are conserved proline sequences within the PAS domains of all HIF-,
which get targeted for degradation under normoxic conditions (Figure 2)(Heikkilä et al.,
2011)(Heikkilä et al., 2011). The structure of HIF-3α is similar to alpha subunits of HIF1
and HIF2, sharing 55% amino acid sequence identity and share similar domain structures
(Figure 2) (Gu, Moran, Hogenesch, Wartman, & Bradfield, 1998).
Both HIF- and  mRNAs are found in normal cells and are constitutively
transcribed and translated into functional proteins. The HIF-1 subunits are constitutively
active in all oxygen conditions. However, in normoxic conditions, HIF-1 proteins are
rapidly degraded and have a typical half-life of five to ten minutes (Chiche et al., 2013, p.
112) (Qingdong Ke & Costa, 2006, p. 1470) (Cunningham, Candelario, & Li, 2012, p. 411)(Q.
Ke & Costa, 2006). Consequently, HIF activation depends mostly on the stability of the
alpha subunit (G. L. Semenza, 2002). Additionally, HIF-1 is constitutively overexpressed
when the von Hippel-Lindau tumor suppressor gene is lost (Y. Liu et al., 2009a, p. 3)(Huang, Gu, Schau, & Bunn, 1998). As mentioned earlier, there are highly conserved
proline sequences in the bHLH and PAS domains of both HIF-1 and 2 proteins that are
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hydroxylated by the enzyme prolyl hydroxylase (PHD). Asparagine sequences are
hydroxylated in the C-terminal protein domain by enzymes called factor inhibiting HIF
(FIHs). Additionally, lysine residues in the oxygen dependent degradation domain of HIF
subunits are acetylated by an acetyltransferase called arrest-defective-1 (ARD1), making it
more favorable for association with the pVHL ubiquitin-elongin complex (Jeong et al.,
2002). Jeong et al found that the activity of acetyltransferases is not influenced by oxygen
conditions and concluded that the ARD1 facilitated acetylation of HIF-1 was irrelevant to
relevant oxygen levels (Jeong et al., 2002). However, both mRNA and protein ARD1 levels
were decreased in hypoxia which leads to the conclusion that there might be relatively
lower levels of acetylated HIF-1 in hypoxia than in normoxia. Overall, all HIF- is
destabilized by the hydroxylation of its proline, asparagine, and lysine segments: and
hydroxylation also serves as a recognition signal for ubiquitination (Denko, 2008)(Stiehl et
al., 2006). The pVHL complex ubiquitinates HIF-1 subunits thereby targeting it for
proteasomal degradation (Qingdong Ke & Costa, 2006, p. 1470)(Stickle et al., 2004). The
pVHL complex is ubiquitously expressed in many tissues and it is mostly localized to the
cytoplasm and thus facilitates HIF- degradation to occur in either the nucleus or the
cytoplasm of normoxic cells (Berra, Roux, Richard, & Pouysségur, 2001)(Berra, Roux,
Richard, & Pouysségur, 2001)(Groulx & Lee, 2002).
In hypoxic conditions, HIF-1 increases in stability and is therefore no longer
targeted for degradation, thereby increasing functional HIF-1 protein subunits (Denko,
2008). Oxygen is a low-affinity substrate for the PHDs and so when oxygen levels decrease,
PHD mediated hydroxylation decreases. Additionally, FIHs are inhibited and HIF-1
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doesn’t get hydroxylated (Denko, 2008); therefore, the inactivation of PHDs and FIHs
prevents HIF-1 ubiquitination mediated proteasomal degradation (Eales, Hollinshead, &
Tennant, 2016). Additionally, HIF-2 has been shown to not be as responsive as HIF-1 to
PDH-2 and PDH-3 induced degradation (Pasanen et al., 2010). This method of
hydroxylation or acetylation-mediated regulation is the primary way HIF-1 gene
expression is regulated, but there are other processes that modulate HIF-1 activity in
tumors as well as for HIF-1 post-translational regulation that are not discussed in this
review (Denko, 2008). In summary, HIF-1 is constitutively expressed, while HIF-1 posttranslational stability is induced by hypoxic conditions (Qingdong Ke & Costa, 2006, p.
1469) (Denko, 2008).
In hypoxic conditions, stabilized HIF-1 translocates to the nucleus where it
dimerizes with HIF-1 (Figure 3) and recruits cofactors such as CPB/p300 (Figure 5)
(Denko, 2008) (Qingdong Ke & Costa, 2006, p. 1470) which bind to hypoxia-responsiveelements (HREs) in the enhancer or promoter regions on target DNA sequences (Chiche et
al., 2013, p. 112)(Denko, 2008)(Pouysségur et al., 2006)(Pouysségur et al., 2006). In this way,
HIF-1/ initiates transcription of target genes associated with decreased mitochondrial
respiration, increased glycolysis, pH regulation, erythropoiesis, apoptosis, survival,
motility, basement membrane integrity, vasodilation, angiogenesis, and hematopoiesis;
these HIF target genes are discussed below (Tanaka et al., 2009)(Qingdong Ke & Costa,
2006, p. 1474) (Chiche, Brahimi-Horn, & Pouysségur, 2010, p. 776)(Chiche, Brahimi-Horn, &
Pouysségur, 2010, p. 776). The HIF family transcriptionally and post-translationally
regulates an expansive set of downstream genes that establishes many of the characteristic
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behaviors of cancer, which makes them a very relevant target to study for future cancer
therapeutics.
HIF-1α is the most widely expressed of the HIFs and has been characterized in head
and neck cancers, ovarian cancer, and oesopharyngeal cancer: all of which have poor
prognosis and are therapy resistant (Talks et al., 2000). Another study found
overexpressed levels of HIF-1 in colon, breast, gastric, lung, skin, pancreatic, prostate, and
renal carcinomas; HIF-1 overexpression was also correlated with cell proliferation in this
study (Talks et al., 2000) (Zhong et al., 1999). HIF-1 mRNA expression has also been
implicated with wound healing (Elson, Ryan, Snow, Johnson, & Arbeit, 2000) which is not
surprising since stem cells grow preferentially in hypoxic environments.

HIF-2
Like the HIF-1α/ heterodimeric complex, HIF-2 has an oxygen regulated subunit
HIF-2α and binds to a HIF-2 complex. HIF-2 expression is characterized in stem cells,
endothelial cells, as well as in glioma stem cells (Covello et al., 2006). Some studies have
shown that HIF-2α has a higher specificity for targeting erythropoiesis, whereas HIF-1 was
said to specifically target glycolytic enzymes (Pasanen et al., 2010). Another study found
that there was higher expression of HIF-2α in high-grade pediatric astrocytoma than in
low-grade astrocytoma; therefore, HIF-2α might correlate with tumor aggression (Khatua
et al., n.d.). These studies indicate overall differential regulation patterns amongst the
members of the HIF family of transcription factors. Some tissues express higher levels of
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HIF-1α than HIF-2α and vice versa (Keith & Simon, 2007) and the differential regulation
also seems to depend of the oxygen concentration. For example, in neuroblastoma samples,
there were strong expression levels of HIF-2α in well vascularized areas. Similarly, in-vitro
neuroblastoma studies at 5% O2, which simulated normal physiological oxygen conditions
of an end-capillary, found stable expression of HIF-2α protein and expression of VEGF, a
common downstream HIF-1α target gene, despite low HIF-1α expression levels. This was
interesting because HIF-2α induced the expression of the same downstream target as HIF1α. When cultured at 1% O2, there was brief stabilization of HIF-1α whereas HIF-2α
protein gradually accumulated and led to a more chronic hypoxia mediated response
(Pasanen et al., 2010). HIF-2α knockdown reduced neuroblastoma growth in athymic mice
which supports that HIF-2α expression correlates with clinical stage, and along with high
VEGF expression, can predict poor prognosis for patients (Holmquist-Mengelbier et al.,
2006)(Pasanen et al., 2010). More generally, this provides evidence that there is
differential expression of HIF-1α and HIF-2α at different oxygen levels, even within the
general classification of a hypoxic environment. These findings also promote the idea that
the HIF regulation differs in acute hypoxia as opposed to chronic hypoxia (Pasanen et al.,
2010). There is also evidence that HIF-2α has a larger role in the GSC population, making it
an important target for continued study (Li et al., 2009).

Induction and Regulation of HIF -3
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The regulation of HIF-3α is not as well characterized as that of HIF-1α and HIF-2α.
There are various reports categorizing the expression levels of the various HIF-3α
isoforms. Some groups have reported that HIF-3αv1 (variant 1) mRNA is upregulated by
hypoxia, while the HIF-3αv4 was downregulated. Another reported that among other splice
variants, HIF-3αv4 was actually hypoxia inducible (Pasanen et al., 2010). RNA interference
experiments also found that HIF-1α and not HIF-2α was responsible for the hypoxia
inducible nature of HIF-3α variants and these findings were also seen in renal carcinoma
Caki cells by Tanaka et al in 2009 (Pasanen et al., 2010)(Tanaka et al., 2009) .
The multiple splice variants of HIF-3α also appear to have differing functions based
on the tissue they are expressed in. It is currently unknown whether HIF-3 mediated
negative regulation of HIF-1 occurs ubiquitously or at all. Other studies have said that the
roles of HIF-3α variants might be more versatile than just negatively regulating HIF-1α and
HIF-2α (Heikkilä et al., 2011)(Heikkilä et al., 2011). More studies are needed to tease out the
role of HIF-3α/ in general as well as in the context of GBM. A set of database studies
predicted that there are three possibly utilized transcription initiation sites on the six
splice variants and found that hypoxia upregulated expression of all three promoter sites.
They also found that the promoter expression was mediated exclusively by HIF-1α
(Pasanen et al., 2010). Some experts claim that rather than HIF-3 regulating HIF-1 and
HIF-2, HIF-3 is oxygen dependent and is instead regulated exclusively by HIF-1, not HIF2. Some studies concluded that the second splice variant of the HIF-3 isoform, HIF3v2, as well as HIF-3αv4, act as a negative inhibitor in HIF-1α and HIF-2α signaling
(Maynard, 2005)(Heikkilä et al., 2011)(Heikkilä et al., 2011). However, one study
investigated this further, but looked into whether shorter cytoplasmic HIF-3 splice
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variants elicited different functions than longer nuclear HIF-3 splice variants and found
varied results (Heikkilä et al., 2011)(Heikkilä et al., 2011). HIF-3 overexpression has also
been shown to decrease the hypoxia regulated expression of VEGF-A and Enolase2 in
human vascular cells (Augstein, Poitz, Braun-Dullaeus, Strasser, & Schmeisser, 2011). More
studies are needed on HIF-3α, but based on the literature, HIF-3α either regulates HIF-1,
or is regulated by HIFs1 and 2. Investigating this inconsistency could prove very useful
to future research. If HIF-3 in fact regulates HIF-1 and HIF-2 and consequently, their
target genes like VEGF-A; HIF-3α could be a great target for future studies.
Target Genes Downstream of HIF
As stated, as many as 100 target genes exist for HIF-1 whose activation can lead to
widespread effects such as angiogenesis, vascular remodeling, erythropoiesis, pH
regulation, cellular proliferation, apoptosis, vasodilation, migration/invasion,
catecholamine and iron, and energy metabolism (Table 1) (Q. Ke & Costa, 2006). There is
some redundancy in the target genes of HIF-1 and HIF-2; both HIFs are hypoxia
inducible and bind to HREs on many of the same target genes (Harris, 2002)(Hu et al.,
2006). Most important for this study are the processes implicated with metabolic
remodeling within the GBM microenvironment and are reviewed below (Denko, 2008).

Angiogenesis
Hypoxia mediated HIF expression mediates tumor progression, largely in part due
to upregulation of genes involved with invasion, metastasis, and new blood vessel growth.
As described above with the Warburg Effect, tumor cells have a growth advantage in
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hypoxic, acidic and nutrient deficient areas. However, tumor cells still have metabolic
requirements and need ways to transport wastes to prevent cell toxicity and death. To
accommodate the need for increased nutrient and waste transport, cancer cells tend to
have upregulated expression of genes involved with angiogenesis. Angiogenesis is a
multistep process involved in creating new vasculature for tissues: this process is hijacked
in cancer. Most notably, the endothelial-specific mitogen called vascular endothelial
growth factor (VEGF), is expressed by cancer cells, which leads to recruitment of
endothelial cells to hypoxic areas and subsequent endothelial cell proliferation (Mansour et
al., 2014), which fails to prevent the “chronic hypoxia” characteristic within areas of the
tumor (Harris, 2002)(Brown & Giaccia, 1998). Activation of VEGF and other angiogenic
factors leads to the creation of more vasculature, which slightly decreases the distance that
oxygen needs to diffuse into tissues while also making nutrient delivery and waste
transport more possible (Q. Ke & Costa, 2006). However, the organization and structure of
the new vessels are weak and hypoxic conditions can remain despite the new vasculature
(Hida & Klagsbrun, 2005). It is unclear how well this tumor-induced vasculature
distributes nutrients to the areas surrounding the tumor. The new blood vessels are
unstable; the new vessels close randomly and then sometimes reopen (Brown & Giaccia,
1998), which provides oxygenated blood to previously hypoxic areas of the tumor in a
process called ‘reoxygenation injury’ (Prabhakar, 2001). Free radicals flood the
surrounding tumor microenvironment and consequently, these areas are resistant to
radiation treatment because radiation targets cells using oxygen free radicals; hypoxic cells
are therefore acclimated to this process already (Wouters & Brown, 1997), which provides
one explanation for the ineffectiveness of radiation as a treatment for some patients.
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Regardless, hypoxia has been implicated with this vascularization process and HIFs
are present in various tissues and in various areas of the tumor microenvironment. Both
HIF-1 and HIF-2 are highly inducible in hypoxic areas, with varying expressions based
on specific oxygen levels of the tumor microenvironment and have also been shown to
upregulate VEGF expression (Holmquist-Mengelbier et al., 2006)(Fukumura et al.,
2001)(Forsythe et al., 1996). Additionally, cancer stem cells have been found to grow in
niches near endothelium (Hira et al., 2015), which seems to correlate to HIF-2 expression
since its expression has been implicated with highly vascularized areas, which typically are
comprised in part of endothelium. Overall, angiogenesis is implicated with poor patient
prognosis in GBM, neuroblastoma, and several other cancers (Holmquist-Mengelbier et al.,
2006)(Pasanen et al., 2010).

Metabolic Remodeling
In low oxygen conditions, HIFs are upregulated and cause downstream changes,
most notably in glucose metabolism. Although less efficient in some ways, cancer cells shift
their metabolism from mitochondrial oxidative phosphorylation to the oxygenindependent process glycolysis but do so aerobically (Figure 4). Since glycolysis only
generates 2 ATP molecules from each glucose molecule (Brahimi-Horn, Chiche, &
Pouysségur, 2007)(Brahimi-Horn, Chiche, & Pouysségur, 2007), more glucose molecules are
required to maintain cancer cell viability and subsequent aberrant growth (Q. Ke & Costa,
2006). This increased glucose uptake into the cell is achieved by up-regulating glucose
transporters, GLUT1 (SLC2A1) and GLUT3 (SLC2A3) (Denko, 2008) (Q. Ke & Costa, 2006).
Since the glucose transporters move glucose according to its concentration gradient, a
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simple upregulation of GLUTs facilitates the increased need for intracellular glucose
(Denko, 2008) (Ozbudak, Karaveli, Simsek, Erdogan, & Pestereli, 2008).
There are numerous uses for the intracellular glucose and most of them have been
directly implicated with HIF-1 (Table 1). The hexokinase (HK) enzymes are responsible for
phosphorylating glucose into Glucose-6-phosphate, which is a charged molecule. The
phosphorylated glucose can no longer escape the cell through the plasma membrane and is
instead utilized in several pathways, including glycoprotein synthesis, metabolized via the
pentose shunt to become ribose, or for glycogen synthesis (Denko, 2008). However,
glucose is mostly utilized by glycolysis by further breakdown and involves the following 12
HIF-inducible glycolytic enzymes: phosphoglucose isomerase (PGI), phosphofructokinase 1
(PFK1), Aldolase, Triosephosphate isomerase (TPI), glyceraldehyde-3 phosphate
dehydrogenase (GAPDH), Phosphoglycerate Kinase (PGK), Phosphoglycerate mutase
(PGM), Enolase, Pyruvate Kinase (PK), and 6-phospho-2-kinase/fructose 2,6
bisphosphatase (PFKFB1-4) (Table 1) (Denko, 2008).
In glycolysis, intracellular glucose is broken down to pyruvate by several enzymes,
including pyruvate dehydrogenase (PDH) (Dengler, Galbraith, & Espinosa, 2014).
However, pyruvate is not utilized by the mitochondria of hypoxic cells and is mostly
converted into lactate by the enzyme lactate dehydrogenase (LDHA) through fermentation.
Excess lactate is one of the two known mechanisms that decreases the intracellular pH and
consequently needs to be shuttled out of the cell to prevent cell toxicity (Harris, 2002).
This is accomplished by releasing lactate into the extracellular space via HIF-inducible
monocarboxylate transporters (MCTs) embedded in the plasma membrane (Table 1)
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(Chiche et al., 2010). MCTs have been implicated in many studies and in-vitro knockdown
has led to in-vitro decreased tumor cell aggressiveness with expected decrease in lactate
shuttling, cell proliferation, invasion, and metastasis; there was also a distinct decrease in
in-vivo tumor formation (Morais-Santos et al., 2015). Carbonic anhydrase (CAIX)
transporters are also important in contributing to the low pH microenvironment by
converting carbon dioxide and water to carbonic acid. In tumors cells with defective LDH,
there is still a low extracellular pH which implies that CAIXs are a factor for the tumor’s low
pH (Yamagata, Hasuda, Stamato, & Tannock, 1998). Transcription of carbonic anhydrase-9
was initiated by hypoxia in several tumor lines (Wykoff et al., 2000) and is suppressed in
normoxic conditions (Loncaster et al., 2001), which implies at least an indirect relationship
with HIFs, with general hypoxia, or with the pH decreases that accompany glycolytic
changes induced by hypoxia. Overall, carbonic anhydrases are expressed in many tumor
types and high expression correlates to poor patient prognosis (Harris, 2002)(Chia et al.,
2001).
The Warburg Effect asserts that hypoxia and subsequent HIF-1 activation are
correlated with lactate and pyruvate accumulation, but it has also been found that lactate
and pyruvate accumulation might also lead to HIF-1 accumulation in both normoxic and
hypoxic conditions (Q. Ke & Costa, 2006)(Denko, 2008)(Marin-Hernandez, Gallardo-Perez,
Ralph, Rodriguez-Enriquez, & Moreno-Sanchez, 2009). As discussed, glycolytic energy
metabolism might be advantageous to tumor cells due to the fast breakdown of glucose to
pyruvate followed with the conversion to lactate via fermentation. Although more ATP per
glucose is produced from mitochondrial oxidative phosphorylation, it is faster to perform
aerobic glycolysis for energy and confers advantage over cells that are restricted to aerobic
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oxidative phosphorylation in the mitochondria, which is also bypassed because of the many
HIF-1 mediated mechanisms (G. L. Semenza, 2010b)(G. L. Semenza, 2010a)(Papandreou et
al., 2006).
In addition to upregulating genes involved with glycolysis, such as glucose
transporters, (GLUTs), HIF-1 indirectly and directly modulates mitochondrial function in
hypoxic cells. HIF-1 indirectly decreases pyruvate flow to the mitochondria by activating
the master kinase, pyruvate dehydrogenase kinase 1 (PDK1) which has been deemed HIFdependent since it requires pyruvate in the Kreb’s cycle to be induced. However, PDK1 is a
confirmed direct transcriptional target of HIF-1. PDK1 is a master kinase that
phosphorylates the E1 segment of the enzyme phosphate dehydrogenase (PDH), thereby
inactivating it. This prevents PDH from breaking pyruvate down irreversibly to Acetyl-CoA,
CO2, and NADH which are used as fuel for the Kreb’s cycle and for the electron transport
chain (ETC) (Denko, 2008). Overall, HIF-activated PDK isoforms directly block the flow of
pyruvate into the mitochondria (R. Thomas, 2001) and prevents oxidative phosphorylation,
total O2 consumption (Papandreou et al., 2006) by the cell, and reactive oxygen species
(ROS) generation (Kim, Tchernyshyov, Semenza, & Dang, 2006). Other HIF-1 inducible
mechanisms are apparent but were not reviewed in this study. Targeting aerobic glycolysis
from multiple approaches might be an effective way to decrease tumor growth.

Glucose Transporters (GLUTs)
GLUT1 and GLUT3 belong to a family of 13 glucose transporters and primarily
regulate glucose transport due to many factors: such as their wide tissue distribution and
affinity for glucose (Denko, 2008)(Ozbudak et al., 2008)(Airley & Mobasheri, 2007). As
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previously discussed, glucose transporters (GLUTs) 1 and 3 have been involved with
hypoxia and are a major component of the metabolic remodeling that is characteristic in
many types of cancer including: endometrial (Ma et al., 2015), gastric (J. Liu et al., 2015),
squamous cell carcinoma (Asmaa Gaber Abdou, MD, Marwa Mohammad Serag Eldien, MD,
& Daliah Elsakka, MD, 2015), ovarian cancer (Labak et al., 2016), meningioma (Nes,
Johannes AP, et al, 2015), and glioblastoma (GBM) (Bache et al., 2015). As expected,
GLUT1 mRNA overexpression is induced by H-ras oncogenic transformation and by
hypoxic conditions (C. Chen, Pore, Behrooz, Ismail-Beigi, & Maity, 2001, p. 9519). Hypoxia
induced HIF-1 expression increases GLUT1 and GLUT3 expression levels (Y. Liu et al.,
2009a)(Rooj, Bronisz, & Godlewski, 2016).
Past research has categorized GLUT-1 and GLUT-3 in various areas of GBM
microenvironments. GLUT1 expression levels differ in different areas of the tumor:
partially a product of hypoxia and of hypoxia-mediated vascularity. HIF-1 stability is
regulated by the severity of the local intra-tumoral hypoxia. Not surprisingly, GLUT1
expression is correlated with the more hypoxic areas of the tumor microenvironment. As
was previously discussed, HIF-1 and HIF-2 correlate with VEGF expression which is the
primary protein responsible for neovasculature creation. Sites of angiogenesis have been
correlated with cancer stem cell niches, as CSCs are commonly found in niches near
endothelial cells, which are the main cells activated by VEGF expression. Transcription of
GLUT1 and the stem cell marker Oct4 have been identified in hypoxic areas of GBM and
when GLUT1 was targeted, self-renewal was inhibited in CSCs. GLUT3 was shown to
regulate Oct4 in embryonic stem cells and is likely implicated in cancer stem cell selfrenewal ability (Christensen, Calder, & Houghton, 2015, p. 4). These studies provide
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further evidence that GLUT1 and likely GLUT3 are correlated with CSC populations within
GBM and indirectly with tumor aggression, treatment resistance, tumor recurrence, and
invasion, to name a few (Labak et al., 2016). Many of the studies investigating the role of
GLUT1 in GSCs haven’t determined whether elevated GLUT1 expression can directly confer
tumor initiating abilities and stem cell self-renewal potential. Recent studies have found
that GSCs have increased glycolytic metabolism compared to non-stem cancer cells
(Hanahan & Weinberg, 2011)(Zhou et al., 2011), which supports the data concluding that
GLUT1 upregulation is more pronounced in GSC populations. It is unknown whether
GLUT1 directly regulates stemness in GSCs, but this is an area for future investigation
(Shibuya et al., 2015). Targeting glycolysis as a cancer therapeutic has limitations due to it
being utilized in many tissues, both healthy and cancerous throughout the body (Hanahan
& Weinberg, 2011)(DeBerardinis, Lum, Hatzivassiliou, & Thompson, 2008). The selective
overexpression of GLUT1 in GSC populations makes GLUT1 a strong contender for future
targeted treatments (Flavahan et al., 2013). There are few therapies developed for GLUT3
expression in CSCs, but its expression in GBM, suggests that it remains a good option for
future targeted GBM therapies (Flavahan et al., 2013).

Summary
The data presented in this study sought to investigate the relationship between
GLUT1 and HIF-1/ in GBM and fibroblast cell lines. A time course assay was completed
to determine if GLUT1 relative mRNA expression levels changed in hypoxic conditions, the
amount of hypoxia exposure was required to induce these changes, and if the GLUT1
expression levels correlate to relative mRNA expression of HIF-1/. This data can be
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utilized for future studies to identify a direct relationship between HIF-1/ heterodimers
and GLUT1 in GBM.
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Lit Review Figures

FIGURE 1: SPATIAL RELATIONSHIP BETWEEN
ENVIRONMENT (S. T HOMAS ET AL ., 2013).

A BLOOD VESSEL , HYPOXIA, AND TUMOR MICRO -

© 2013 by MDPI (http://www.mdpi.org). Reproduction is permitted for noncommercial
purposes.
The figure above depicts the correlation HIF-1 expression and relative oxygen
concentration in the context of hypoxic tumor microenvironment in tumors and their
proximity to blood vessels. In normoxia, HIF-1 subunits are rapidly degraded, but the
mechanisms that degrade them in normoxia are less effective in hypoxic conditions
resulting in stabilized HIF-1 and subsequent translocation in the nucleus where it binds to
HIF-1 which together comprise an active HIF-1 heterodimeric protein.
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FIGURE 2: DOMAIN STRUCTURES OF HIF TRANSCRIPTION FACTORS (LISY & PEET, 2008).
Adapted by permission from Macmillan Publishers Ltd: Cell Death and Differentiation, (HIF
Transcriptional Activity), Copyright 2008.
The three HIF paralogs: HIF-1, HIF-2, and HIF-3 and the HIF-3 splice variant called
inhibitory PAS domain protein (IPAS) which might to negatively regulate HIF-1 mediated
transcription, but this is controversial. All the HIF alpha subunits hetero-dimerize with
HIF-/ARNT subunits, possibly except for the IPAs HIF-3 splice variant, which might only
bind to a specific HIF-3 subunit. All the HIFs possess highly similar bHLH and PAS
domains which mediates the characteristic HIF-/ hetero-dimerization and DNA binding.
All the HIF- subunits contain oxygen dependent domains (ODDDs) and N-terminal
transactivation domains (NADs). The oxygen dependent domains (ODDDs) contain the
proline sequences that are hydroxylated by PHDs in normoxic conditions, as discussed in
Figure 6 and Chapter 1. The hydroxylation of these sequences and others targets HIF-1
for proteasomal degradation which confers HIF- instability in normoxic conditions. HIFs
1 and 2 contain oxygen dependent C-terminal transactivation domains (CADs). Both CADs
and NADs facilitate the recruitment of coactivators and transcription intermediates to the
HIF- / complex which facilitates association with transcriptional activation of HIFdownstream genes.
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FIGURE 3: HIF DIMERIZATION AND DNA BINDING.
Adapted by permission from Macmillan Publishers Ltd: Cell Death and Differentiation, (HIF
Transcriptional Activity), Copyright 2008.
After HIF- stabilization, it translocates to the nucleus and binds to the constitutively active
HIF-1 subunit, forming a heterodimeric complex. The heterodimerization of the complex
is essential to binding to HRE binding. The basic residues near the N-terminus of each
protein facilitates binding to the nucleotides of the hypoxia response element (HRE) in the
promoter region of DNA sequences of target genes (Lisy & Peet, 2008). The heterodimeric
HIF-/ also recruits cofactors and RNA polymerase II and initiates transcription genes
that mediate cell metabolism, angiogenesis, erythropoiesis, and many other properties that
are normal an also that can promote cancerous phenotypes.
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FIGURE 4: THE WARBURG EFFECT (VANDER HEIDEN , 2009)
Adapted by permission from American Association For The Advancement Of Science:
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
The figure above depicts the major differences between normal cellular metabolic
processes and abnormal cancer metabolism. When in the presence of oxygen,
differentiated and non-proliferating tissues metabolize a portion of their glucose into
pyruvate anaerobically in the cytoplasm by glycolysis, which produces 2 ATP. Then in
environments with oxygen present, oxidative phosphorylation completely oxidizes most of
the pyruvate made in glycolysis in the mitochondria. Oxygen is required for oxidative
phosphorylation to occur, as oxygen is the final electron acceptor for oxidizing glucose.
When oxygen is reduced, the pyruvate generated by glycolysis can be used to generate
lactate by anaerobic fermentation as opposed to mitochondrial oxidative phosphorylation,
which is only done aerobically. Generation of lactate cycles NADH into NAD+ and
propagates glycolysis repeatedly. Warburg found that cancer cells and normal proliferating
cells convert most of their glucose to lactate despite whether oxygen was present, aerobic
glycolysis. Despite the mitochondria being used less for oxidative phosphorylation, it is
fully functional at producing ATP.
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FIGURE 5: MECHANISMS OF HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) STABILIZATION
Adapted by permission from Macmillan Publishers Ltd: Nature Reviews, Cancer (Hypoxia,
HIF1 and glucose metabolism in the solid tumour), Copyright 2008.
HIF-1 is unstable in well-oxygenated tissues due to many mechanisms that degrade it
within five to ten minutes of its translation (Chiche et al., 2013, p. 112) (Qingdong Ke &
Costa, 2006, p. 1470) (Cunningham et al., 2012, p. 411)(Q. Ke & Costa, 2006). However,
HIF-1 stabilization can be a product of a hypoxic environment or oncogene activation
associated activation of genes such as Ras, RAF, MAPK, phosphoinosotide-3 kinase (PI3K),
PTEN, or Akt pathways. In Figure 6a, the HIF-1 domain structure is shown. In normoxia,
the proline (P) sequences 402 and 546 and the asparagine (N) 803 sequences are
hydroxylated thereby targeting the HIF-1 protein for degradation. In Figure 6b, the
classical pathway of HIF-1 stabilization is depicted. In normoxia, the very conserved
bHLH and PAS domains of HIF-1 have proline sequences (P) that are hydroxylated by the
enzyme prolyl hydroxylase (PHD); the asparagine sequences (N) are hydroxylated by
enzymes called factor inhibiting HIF (FIHs). HIF-1 hydroxylation of the various proline,
asparagine, and lysine (discussed in Chapter 1) serves as a recognition signal for
ubiquitination (Denko, 2008)(Stiehl et al., 2006). The hydroxylated proline sequences are
recognized by the ubiquitin ligase pVHL that is complexed to elongins B and C, which
makes the VHL-elongin complex shown above (Jeong et al., 2002) (Stickle et al., 2004). The
VHL complex binds to the hydroxylated proline sequences and ubiquitinates it and thus
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targets it for proteasomal degradation (Qingdong Ke & Costa, 2006, p. 1470)(Stickle et al.,
2004). However, in hypoxic conditions, the PHD and FIH enzymes do not function as
effectively and HIF-1 protein remains stable because it is no longer targeted for
degradation (Denko, 2008). Additionally, Kreb’s cycle intermediates such as succinate or
fumarate or mitochondrial reactive oxygen species (ROS) can also inhibit the function of
PHDs which would also lead to increased HIF-1 stabilization and subsequent heterodimerization with the constitutively active HIF-1 subunit. This heterodimeric complex
then translocates to the nucleus of the cell before binding to the hypoxia response element
(HRE)
in
the
promoter
region
of
target
DNA
sequences.
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T ABLE 1: HIF-1 TARGETS THAT REGULATE GLUCOSE METABOLISM (DENKO , 2008).
Adapted by permission from Macmillan Publishers Ltd: Nature Reviews, Cancer (Hypoxia,
HIF1 and glucose metabolism in the solid tumour), copyright 2008.
Expression of hypoxia inducible factors (HIFs) has been shown to mediate much of the
characteristic metabolic remodeling that occurs in cancer cells. Specifically, glucose entry is
upregulated by upregulating expression of GLUT1 and GLUT3 transporters. Additionally,
glycolytic enzymes are upregulated to promote glycolysis and fermentation as opposed to
the normal aerobic oxidative phosphorylation that occurs after brief glycolysis. Also,
monocarboxylate transporters are upregulated to shuttle out the excess lactate that gets
produced by fermentation, to promote continued cell viability.
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Objectives and Hypotheses

Many studies have discussed the roles of HIF-1 and GLUT1 in cancer metabolism.
However, it is unknown whether there is a direct relationship between them in a
Glioblastoma (GBM) in-vitro model. In other systems, the heterodimeric HIF-1/ complex
binds directly to the Hypoxia Response Element (HRE) on the GLUT1 promoter to drive
expression of GLUT1 (Amann et al., 2009). In this study, changes in HIF-1 and GLUT1
relative mRNA expression were measured in response to changes in relative oxygen
concentrations utilizing reverse transcription followed by End-Point Polymerase Chain
Reaction (EP-PCR) and Quantitative Polymerase Chain Reaction (qPCR) in a GBM in-vitro
model. EP-PCR was conducted to test whether the genes of interest were expressed at all.
Then qPCR was conducted to quantify the amount of mRNA transcripts that were
transcribed over time in a hypoxic environment.
Hypothesis 1: GLUT1 and HIF-1 expression in GBM cell lines is directly correlated with invitro hypoxic conditions.
Overall Research Questions:
•

Does the expression of HIF-1 and GLUT1 transcripts change in hypoxic conditions?
How long are hypoxic conditions required to induce these changes?

36

•

Does HIF-1 gene expression directly correlate with GLUT1 and relative oxygen
concentrations?

Aim 1: Determine the presence or absence of HIF-1, HIF-1, and GLUT1 in U87MG GBM
cells and in MSU1.1 cells in both in-vitro normoxic and hypoxic environments using EP-PCR
and gel electrophoresis.
•

Aim 1a: Generate and test the designed PCR primers and confirm the presence or
absence in expression of HIF-1, HIF-1, and GLUT1 in both U87MG GBM cells and
MSU1.1 cells.

•

Aim 1b: Characterize the presence or absence of expression of HIF-1, HIF-1, and
GLUT1 in both normoxic (20% O2) and hypoxic (5% O2) environments using EP-PCR
and gel electrophoresis.

Aim 2: Quantify the relative expression levels of HIF-1, HIF-1, and GLUT1 in GBM using
qPCR.
•

Aim 2a: Quantify relative gene expression levels of HIF-1, HIF-1, and GLUT1 in
both U87MG glioblastoma cells and MSU1.1 fibroblast cells while grown in-vitro in a
normoxic control (20% O2) environment.

•

Aim 2b: Quantify relative gene expression levels of HIF-1, HIF-1, and GLUT1 in
both U87MG glioblastoma cells and MSU1.1 fibroblast cells while grown in-vitro in a
hypoxic environment (5% O2).

Aim 3: Determine whether there is a positive correlation between relative expression of
HIF-1, HIF-1, and GLUT1 in U87MG and MSU1.1 cells and whether it correlates with invitro hypoxic conditions over time (0, 3, 6, 12, or 24 hours).
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Methods

PCR Primer Design

Splice variants of the genes of interest were evaluated using the UCSC Genome
Database. The NCBI Gene Bank provided further information about splice variants and the
mRNA sequences. The NCBI primer design tool was used to pick primers that amplified the
exon-exon junctions, to amplify mRNA sequences of the genes of interest. Primers were
picked based on their predicted PCR amplicon size. The primers with predicted amplicons
between 80-400 bp were chosen, as they would be more successful in both End-Point and
qPCR. The IDT Oligo Analyzer tool (www.idtdna.com) was used to ascertain the likelihood
of the primers forming primer dimers and other secondary structures, as they impede
successful PCR. Further information on the designed PCR primers is shown in Table 2.

Cell Culture
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Human Glioblastoma cell lines U87MGMG and LN229 cells as well as the human
foreskin fibroblast line MSU1.1 were utilized in this study. Both U87MG and LN229 cell
lines are commonly used as in-vitro models for glioblastoma research studies. MSU1.1 is a
fibroblast cell lines and was used as a control cell line due to their non-cancerous
phenotype. Although the efficacy of using MSU1.1 cells as a control is a limiting factor in the
study, it was deemed the most appropriate option available to us. The use of MSU1.1 cells
in this study was also highly controlled; passage numbers were kept as low as possible and
cells were not grown past 65% confluency to minimize the chance of changes to the cell
that acquire different characteristics like a cancer cell or cancer cell line.
All cell lines were removed from cryostasis in liquid nitrogen and revived back into
culture. Cell cultures were expanded in T-75 flasks and then frozen back in 1.5 mL aliquots
of freeze media at a ratio of 10% DMSO and 90% Media. Frozen aliquots were placed in
cryostasis for the ease of culturing cells as needed for experimental assays. This method
helped to control for gene expression changes that would potentially occur because of
differing cell passage numbers.
All cultured cell lines were expanded in standard cell conditions of 37C, 5% CO2,
20% O2 at 100% humidity. U87MG and MSU1.1 cells were cultured in EMEM + 10% Fetal
bovine serum (FBS) (Atlanta Biological, Atlanta, GA). LN229 cells were cultured using MEM
+ 10% FBS. U87MG and LN229 cultures were expanded in T-75 cell culture flasks until they
were 70-80% confluent. LN229 cells were discontinued from the project due to time and
budget constraints. MSU1.1 cultures were only grown to approximately 60% confluency to
minimize any chance of phenotypic changes induced by over-growth. For the hypoxia time
course assay, cells were plated and were grown in a normoxic (20% O2) environment
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overnight (12-15 hours), were washed with 1X PBS (Lonza, Cat# 17-516F/12), to remove
any cellular wastes that had accrued overnight followed by the application of fresh cell
media. The cells were then placed in the hypoxic chamber (5% O2) for various amounts of
time.

Hypoxia Time Course Assay: Cell Culture Design

In this experiment, hypoxic conditions of 5% oxygen were used as the treatment
prior to gene expression analysis. In preparation for each assay, cells were revived from
cryostasis, split once in a 1:4 ratio and were then plated for the assay immediately after the
last cell culture split. Cells were split in this manner and were not counted due to time
constraints. Experimental cells were plated in 10 cm treated cell culture plates at 30-50%
confluency and the and the cells adhered to the plate overnight (approximately 12-15
hours) in the presence of 20% O2 chamber.
The following morning, the experimental cell plates were removed from the
incubator. The cell culture media was aspirated, and cells were washed with 2-3 mL of
sterile 1% PBS. The cells were then fed 10 mL of fresh media, respective to each cell line.
The experimental cell cultures were then transferred to the hypoxic (5% O2) chamber for
specified times of 3 hours, 6 hours, 12 hours, and 24 hours. The control cells were only
grown in normoxic conditions, were either lysed after spending 0 hours in hypoxia or after
24 hours of growth in hypoxia. In the data analysis below, the control cells are referred to
as 0 hours spent in a hypoxic chamber. At each time point, the cell culture dishes were
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removed individually from the hypoxic chamber and were lysed directly in their cell
culture plates using the RLT lysis buffer from the Qiagen RNeasy kit (Cat# 74104). This
was repeated for each of the three biological replicates for each hypoxia exposure time
point in the assay. Overall, the experiment was done once, but included three biological
replicates for each hypoxia time point or control sample.

Hypoxia Time Course Assay: Direct Cell Lysis

Direct cell lysis in 10 cm cell culture plates, as opposed to T-75 flasks, to allow for
quicker cell lysis. The direct cell lysis was done to reduce any potentially reversible
changes in the hypoxia induced gene expression from occurring. In total, three control
(normoxia exposed) plates were lysed and three cell experimental culture plates grown in
hypoxia were lysed after each time point in the assay: 3 hours, 6 hours, 12 hours, or 24
hours. This design was repeated for each cell line: MSU1.1 (control), LN229 (glioblastoma),
and U87MG (glioblastoma). However, LN229 was quickly removed from the project due to
time and budget constraints.

RNA Isolation and First Strand cDNA Synthesis

RNA was isolated and homogenized using a QiaShredder (Qiagen, Cat # 79654).
RNA was isolated from cell lysates using a RNeasy mini kit (Qiagen). The full RNA isolation
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procedure is included in Appendix C. The isolated RNA was quantified using a
ThermoScientific Nanodrop 2000c. The RNA was then converted into single strand cDNA
using either Promega AMV Reverse Transcriptase (Promega, Cat # M5108) or
ThermoFisher Maxima Reverse Transcriptase (Cat # EP0741) and incubated in a Bio-Rad
T100 Thermal Cycler. Further details on cDNA synthesis are included in Appendix A. All the
qPCR data collected was with cDNA synthesized using the ThermoFisher reverse
transcriptase and the Promega RT was utilized only in the End-Point PCR.
Relative mRNA expression levels were analyzed in place of the proteins in question.
This method confirmed that the mRNA coding for the hypoxia inducible factor family of
transcription factors was being transcribed. The presence or absence of mRNA of the alpha
and beta subunits of HIFs 1-3 were evaluated with End Point PCR (EP-PCR). HIF-1α and
HIF-1 were evaluated further using Quantitative Real Time PCR (qPCR) to note the
relative expression levels. Since the transcription and translation of glucose transporters,
specifically GLUT1, is elevated in certain cancers, the transcription of GLUT1 was also
evaluated in this study with EP-PCR and qPCR.

End-Point Polymerase Chain Reaction

End-Point PCR (EP-PCR) was conducted to determine whether the designed PCR
primers were functional and then to determine presence or absence of HIF-1α, HIF-1, and
GLUT1 mRNA transcripts in both normoxic and hypoxic environments. Additional genes of
interest were evaluated in the End-Point PCR study: HIF-2α, HIF-2, HIF-3α, HIF-3, and
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GLUT3. End-Point PCR was conducted on samples from U87MG-MG, LN229, and MSU1.1
cells.
The reaction was performed using a Bio-Rad T100 Thermal Cycler. The program
initiated at 95C for 3 minutes. Then the reaction performed 35 cycles of: 95C for 30
seconds for denaturing, decreased to 55C for 30 seconds for primer annealing, and was
raised to 72C for 1 minute for DNA elongation. After the 35 cycles, the reaction was
terminated with an incubation at 72C for 5 minutes before incubating at 12C. The PCR
product was either subjected to gel electrophoresis or was stored at -20C freezer.
To determine the presence of DNA products produced from the End-Point PCR
reaction, the products were electrophoresed in a 1.0% agarose gel in Tris/Borate/EDTA
(TBE) buffer. When the mixture was cool to the touch, 1 L of 10 g/L ethidium bromide
was added to the solution and then was mixed. The mixture was further cooled in the fume
hood and was then poured into a standard gel box setup. A total of 5 L of Blue/Orange 6X
Dye (Promega, Cat# G1881) was added to each 25 uL PCR product, yielding a total 30 L
total volume per lane. A 1kb and/or a 50 bp ladder were included on each gel. The gel
electrophoresis was conducted using the following parameters; ~120 V, for 60-75 minutes
in a running buffer solution comprised of 0.5x TBE buffer. Gels were imaged using a NMU
Gel Doc Imaging System (BioRad, Hercules, CA).

Real Time (Quantitative) Polymerase Chain Reaction
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Real time PCR (qPCR) was conducted to determine the amount of time that was
needed to induce relative expression changes to occur in HIF-1α, HIF-1 and GLUT1 mRNA
expression levels after exposure to hypoxic conditions (5% O2).
The real-time PCR (qPCR) reaction was performed with the GoTaq qPCR Master Mix
(Promega, Cat# A6001). The master mix consisted of a propriety SYBR green dsDNA
intercalating dye, primers, dH2O, and a low level of carboxy-X-rhodamine (CXR) reference
dye. The reaction size recommended by the manufacturer was 50L, but the reaction size
was scaled down to 20L to minimize project cost. The small volume necessitated extra
care to be taken in pipetting evenly throughout all the individual PCR reactions. The 20 L
reaction had the following components:
10 L Master Mix
0.2 L CXR reference dye
0.8 L Forward Primer
0.8 L Reverse Primer
7.4 L Nuclease-free water
Total: 19.2 L Master Mix

A total of 19.2uL of master mix without primers was added to each of the three
negative control wells in the 48 well sample PCR plate. 0.8uL of PCR grade nucleotide free
water (Promega, Cat#A6001) was added to each of the control wells. 0.8 L of cDNA was
added to the experimental plates. 20uL total volume was added to each well in the 48
sample PCR plate. The reaction was performed using an Applied Biosciences StepOnePlus
thermocycler and was programmed for 1 cycle at 95C for 10 minutes and then 40 cycles of
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15 seconds at 95C to denature the cDNA, followed by a decrease in temperature to 55C
for 1 minute for annealing, and then increased for elongation to 73C for 30 seconds.
In qPCR, fluorescent signal is accumulated and denotes a positive signal in the PCR
reaction. The number of cycles needed for the accumulated fluorescence to pass a
threshold value is referred to as the cycling threshold (CT) value. CT values are inversely
proportional to the amount of nucleic acid. Therefore, housekeeping genes or highly
expressed genes will have a low CT value. The comparative Ct method was used to analyze
the data which was exported to Excel. The comparative Ct method was used to analyze
gene expression levels, as it seemed appropriate due to having a large sample size:
differently treated samples, two cell lines, and three genes of interest (Wong & Medrano,
2005). This method involves normalizing the gene of interest to a house keeping gene:
GAPDH in this case to calculate a delta Ct (dCt) (Brugè, Venditti, Tiano, Littarru, & Damiani,
2011)(Brugè, Venditti, Tiano, Littarru, & Damiani, 2011). The delta Ct values of the hypoxia
treated cells were compared to the delta Ct values of the normoxia exposed (control) cells
to get a delta delta Ct (ddCT) value (Livak & Schmittgen, 2001). Relative gene fold change
was calculated by 2^-(delta delta Ct). Relative fold change shows whether there is any
change in relative gene expression. A fold change above a value of one denotes a gene upregulation; a negative value for relative gene fold change indicates that the gene was downregulated, thereby reducing the number of gene transcripts made (Wightman, 2016).
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Statistical Analysis

Many methods were initially used to test the significance of the qPCR data including
factorial analysis using SPSS software and GraphPad-PRISM software for two-way ANOVA
with repeated measures and student t-tests. Two-way ANOVA was utilized to create graphs
depicting mRNA expression fold change of GLUT1, HIF-1 α, and HIF-1 in U87MG cells and
MSU1.1 cells at each of the time points in the hypoxia time course assay (Figures 11-13).
However, more in-depth analysis was needed to determine which variables had
correlative relationships. The large number of dependent variables in the study: three
genes of interest, two cell lines, and five treatment time points, using a factorial cell culture
setup, necessitated the use of a multivariate analysis of variance, MANOVA (Stevens,
2009)(Warne, 2014). The data was log transformed and then was analyzed with MANOVA
using SPSS software. One outlier was present in the data and was removed from the data
set. However, the removal of the outlier did not significantly change the results of the
MANOVA analysis. MANOVA is an extension from the univariate analysis of variance
(ANOVA). An ANOVA can evaluate the statistical differences among a single dependent
variable. For example, an ANOVA could determine whether there were changes in the
relative expression of GLUT1 as a product of the time spent in a hypoxic environment. The
MANOVA can evaluate the effects of several dependent variables and compiling them to
create a single continuous variable. This study analyzed the effects of cell line (U87MG and
MSU1.1) as well as the combined effects of both hypoxia treatment and cell line. The
independent variable in the study was the time that cells spent in either normoxic (control)
or hypoxic (experimental) environments prior to being lysed for subsequent RNA isolation.
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The many multiple dependent variables in the study necessitated the use of a MANOVA to
understand whether any statistical significance was due to variance within any of the
dependent variables or whether it was due to the time spent in a hypoxic environment
(independent variable). Pairwise comparison analyses were conducted to find correlations
between the expression levels of the genes of interest in the cell lines that were tested
while also testing whether different amounts of time in a hypoxic environment also had an
effect (Tables 8-12). These pairwise comparisons were depicted visually in Figures 14-16.

Limitations of Study

Limitations were present in the usage of MSU 1.1 cells as a control line, as they are a
cell line made by transfecting diploid fibroblasts with the viral v-Myc gene (Hurlin, Maher,
& McCormick, 1989) . Making a cell line inherently gives the cells, cancerous or not,
different genetic and phenotypic profiles that limit the replicability of the study as well as
the applicability when applying this study to in-vivo GBM studies. However, the growth of
MSU1.1 cells was carefully controlled in this study: cells were not grown past their
recommended confluency and were examined carefully for any phenotypic changes prior
to hypoxic exposure and subsequent lysis. Since normal human control cells were not
readily available, the MSU 1.1 fibroblast cell line was used. Although the sample size for
PCR was relatively small, there were sufficient replicates done for the data sets to pass the
needed statistical tests for variance and normality. Likely due to human error there was
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some variability in the delta CT values. However, this variability was accounted for in the
statistical analysis and proved to be insignificant.
T ABLE 2: PCR PRIMER SEQUENCES
The following sequences were designed for this study and were utilized in EP-PCR and
qPCR studies. As discussed on page 29, PCR primers were designed to have predicted
amplicon sizes between 80-400 base pairs, to increase qPCR success, as small amplicons
sizes are required to have successful qPCR. All primers were utilized in EP-PCR and qPCR
studies and tested for expression of the following target genes in U87MG and MSU1.1 cells:
HIF-1α, HIF-1 sets 1 and 2, HIF-2α, HIF-2, HIF-3α, HIF-3, GLUT1, and GLUT3.
Primer

Forward Primer Sequences (5'-3') Reverse Primer Sequences (5'-3')

Use of Primer

HIF-1α

ACCTATGACCTGCTTGGTGC

GGCTGTGTCGACTGAGGAAA

End Point and qPCR

HIF-1b Set 1

CCCCACCCAAGGAGCAA

AGAAAAGCCTGAGCGGGTAGT

End Point and qPCR

HIF-1b Set 2

CTTTTCTGCCCAGGTGGCTA

ATGGAGTCTGAAAGCTGCCC

End Point PCR

HIF-2α

TACAATCCTCGGCAGTGTCC

GAGGCTGTCAGACCCGAAAA

End Point PCR

HIF-2b

CGGCAGCTAAACCAGAGTCA

ACTTTCAGCGAACCCTGGAG

End Point PCR

TAGCAGGCATCCAGTGGTTC

End Point PCR

HIF-3α Set 1 ATAAGTCAGGGAGGGGACAGAG
HIF-3α Set 2

CACTGAGGCAGTGGAGACAG

GGCTCATTCAGGTTCAGGAGT

End Point PCR

HIF-3α Set 3

GACACTGAGGCAGTGGAGAC

CATTCAGGTTCAGGAGTGGGG

End Point PCR

HIF-3b

AGAAGGTGGCCCAAAGAGGA

GGAGGCGTACTCGTGATGTT

End Point PCR

GLUT1

GTGACAAGACACCCGAGGAG

CCTGGAGCCGTTAAGTCCTG

End Point and qPCR

GLUT3

GGAAAGGGCAGGAAGAAGGA

ACAGTCATGAGCGTGGAACAAA

End Point PCR

48

Results

In previous work, the heterodimeric HIF-1 complex activity was shown to positively
correlate with a hypoxic tumor microenvironment (G. L. Semenza, 2002). After hypoxia
induced stabilization of HIF-1, the HIF transcription factor translocated to the nucleus and
bound to the hypoxia response element on target DNA: one such target is GLUT1 (G. L.
Semenza, 2010b). This study sought to establish the relative mRNA expression levels of
HIF-1α, HIF-1, and GLUT1 in U87MG GBM and MSU1.1 fibroblast cells in hypoxic and
normoxic conditions. Additionally, this study sought to determine whether there is a direct
correlation between HIF-1 and GLUT1. As a first step, we investigated whether HIF-1α/
heterodimeric complexes were being transcribed into mRNA. This study served as a
precursor step to future studies investigating the HIF-1 complex at the protein level and its
interaction with GLUT1.
PCR primers for HIF-1α, HIF-1, HIF-2α, HIF-2, HIF-3α, HIF-3, GLUT1, and GLUT3
were designed (Table 2) and tested using End-Point PCR and subsequent gel
electrophoresis for U87MG cells. HIF-1α and two sets of HIF-1 products from U87MG cell
lysates were detected in both normoxic and hypoxic conditions with the correct band
length for their expected PCR product sizes: 98 bp (HIF-1α), 55 bp (HIF-1-Primer Set 1),
and 80 bp (HIF-1-Primer Set 2) (Figure 6). Similarly, in Figure 7, the PCR products for
HIF-2α (183 bp) and HIF-2 (234 bp) are shown at the correct product size. HIF-3α
amplification was not conclusively established in U87MG cells in this study. There were
multiple bands in lanes 8 and 9 rather than having a single band of 70 bp using one of two
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primer sets designed for HIF-3α (Figure 7). The second primer set designed for HIF-3α
should have had a product of 72 bp in lanes 2 and 3 of the gel shown in Figure 8. Both
attempts to detect a PCR product for HIF-3α using either primer set were unsuccessful.
However, there was successful amplification of HIF-3 (177 bp) and GLUT1 (231 bp) in
U87MG cells (Figure 8). GLUT3 expression was also found in U87MG PCR reactions from
both U87MG cells in a normoxic and hypoxic environment (Figure 9). In Figure 10, the
presence of HIF-1α, HIF-2α, HIF-2, HIF-3α, HIF-3, and GLUT1 were tested in MSU1.1 cells
(Figure 10) and the presence of all but HIF-3α were confirmed.
Overall, the expression of genes HIF-1α, HIF-2α, HIF-2, HIF-3, GLUT1, and GLUT3
were observed in U87MG cells in normoxic and hypoxic conditions. GLUT3 expression was
not tested in MSU1.1 cells using EP-PCR. Most of the primers were tested in MSU1.1 cells
grown in hypoxia for 48 hours, except for HIF-1, due to issues designing an effective PCR
primer (Figure 10). However, HIF-1 expression was measured using qPCR. Agarose gels
were also run using normoxic control cDNA from MSU1.1 cells (data not shown).
There were also recurrent issues with designing a HIF-3α primer. Preliminary EPPCR experiments could not confirm HIF-3α expression in either U87MG cells or in MSU1.1
cells. Inappropriately sized bands were present in all EP-PCR amplification agarose gels
conducted with U87MG cell mRNA (Figures 7 and 8) and in MSU1.1 cell mRNA samples
(Figure 10). Consequently, the study of HIF-3 was discontinued and subsequent qPCR
experiments were not performed. New PCR primers were needed to continue the study of
HIF-3 but a new set of primers was not designed due to time and budget constraints.
The End-Point PCR was followed up with qPCR to measure the relative mRNA
expression levels of HIF-1α, HIF-1, and GLUT1 in U87MG and MSU1.1 after hypoxia
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exposure for 0, 3, 6, 12, or 24 hours. The resulting CT values for each gene for each run of
qPCR that was conducted. These values were compiled and the technical replicate values
for each biological replicate were averaged (data not shown). As discussed previously, the
comparative CT method was utilized to analyze the results of each qPCR. This method is
described below using GLUT1 as the example gene of interest.
Equation 1: Calculate the

of hypoxia treated relative genes (Experimental Treatment)

Equation 2: Calculate the

of normoxia treated qPCR runs (Control treatment)

Equation 3: Calculate the difference between ∆CT Hypoxia (Experimental Treatment) and
∆CT Normoxia (Control Treatment).

Using Equation 1, the delta CT values were calculated for each gene of interest after
exposure to hypoxia at the various time points in the hypoxia time point assay. These delta
CT values were referred to as ‘∆CT (hypoxia treated)’. Then in Equation 2, the delta CT
values of the normoxia exposed gene of interest, GLUT1, were measured and then
normalized to the CT of the normoxia exposed housekeeping gene GAPDH. In Equation 3,
the ∆∆CT of GLUT1 was calculated by normalizing the effects of hypoxia to the effects
shown in normoxia. The ∆CT values for each gene of interest measured at each time point
in the hypoxia time point assay in both U87MG and MSU1.1 cells are depicted in Table 4.
The ∆∆CT values were converted into relative fold change by using Equation 4 below.
Equation 4:
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The relative fold change data was log transformed and one outlier was removed
from the data, which did not significantly change the overall results (data not shown). The
data was then analyzed for significance using Multivariate Analysis of Variance (MANOVA)
using SPSS software. MANOVA was conducted to test whether each of the independent
variables: cell line, relative oxygen concentration, and time spent in variable relative
oxygen conditions had effects on the dependent variables: the expression of the genes HIF1α, HIF-1, and GLUT1. In this study, several multivariate test statistics were used: Wilks’
Lambda, Pillai’s Trace, Hotelling’s Trace, and Roy’s Largest Root, shown in Table 4. Of
interest was the Wilks’ Lambda statistic from the F test, which represents the percentage of
variance within the dependent variables, which are the genes of interest: HIF-1α, HIF-1,
and GLUT1. The desired result entails that the p-value denoting significance fall in the
range of zero to one, ideally as close to zero as is possible.
The Wilk’s Lambda test indicated that there was a statistically significant effect
(p=0.000) between the independent variable, cell line, and the expression level of all the
dependent variables when analyzed together as a group: HIF-1α, HIF-1 , and GLUT1
(Table 4). Likewise, the other independent variable, hypoxia treatment, had a statistically
significant effect (p=0.000) on the expression levels of the entire group of genes of interest:
HIF-1α, HIF-1 , and GLUT1 (Table 4). It was hypothesized that both HIF-1α, HIF-1, and
GLUT1 expression levels would be directly proportional to in-vitro hypoxic conditions.
Therefore, our null hypothesis was rejected in regard to the expressions of HIF-1α and
GLUT1 and confirmed for HIF-1 expression. It was expected that both HIF-1α and HIF-1
expression would be proportional to relative oxygen concentrations in GBM cells as HIF-1
expression has been found in several types of cancer (C. Chen et al., 2001, p. 1) (G. L.

52

Semenza, 2007). Likewise, it was expected that GLUT1 expression would also increase in
hypoxic conditions, as it is thought to be directly downstream from HIF-1, as well as HIF-2
and possibly HIF-3 in an indirect manner (Richardson, Knowles, Tyler, Mobasheri, &
Hoyland, 2008). GLUT1 upregulation has been identified in several types of cancer (Amann
et al., 2009, p. 1)(Krzeslak et al., 2012).
The combined effects of the two independent variables (cell line and hypoxia
treatment) had significant interactional effects (p=0.004) on the expression of HIF-1α, HIF1, and GLUT1 as well (Table 4). Overall, the multivariate analyses supported our
hypothesis in the context of all the genes of interest when they are lumped together as one
dependent variable. Additionally, the significance values found with the Wilk’s Lambda
analysis were also seen with the other three multivariate tests mentioned above and are
shown in Table 4. However, the multivariate analyses were not capable of determining
whether the independent variables, cell line and hypoxia exposure, led to expression
changes in each individual gene.
This general significance found using the MANOVA overall test necessitated further
study of the effects that each independent variable had on the entire group of dependent
variables, the genes of interest (HIF-1α, HIF-1, and GLUT1) (Table 5). To conduct this
analysis, two-way ANOVAs were utilized and can be visualized in Figures 14-16. The
results from these ANOVAs concluded that the independent variable, cell line, had a
significant univariate effect on the dependent variables of HIF-1α expression (p = .001) and
GLUT1 expression (p = .000). Cell line had a significant control over the expression of these
two genes individually. Therefore, the affected expression levels of HIF-1α and GLUT1
cannot be correlated to one another from the data provided in Table 5. This ANOVA also
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identified that the in-vitro hypoxia exposure had a single univariate effect on the expression
of the following genes: HIF-1 (p = .018), and GLUT1 (p = .000). When the effects of both
independent variables (cell line and hypoxic treatment) were combined, there was only a
significant effect seen in GLUT1 expression (p = .002), shown in Table 5. Overall, this
univariate ANOVA was useful in determining the effects that each independent variable had
on each dependent variable (gene expression levels) individually but could not correlate
the effects seen in the dependent variables together as was possible in the MANOVA
depicted in Table 4.
In this study, a two-way MANOVA (Table 4) and multiple univariate ANOVAs (Table
5) were utilized to analyze the gene expression data from the qPCR gene expression
studies. To better understand the data collected, a MANOVA was used. The two-way
MANOVA revealed that there were statistically significant effects on gene expression levels
from the following independent variables: cell line, hypoxia exposure treatment, and
interaction effects from the combined effects of cell line and hypoxia exposure treatment
(Table 4). Subsequent two-way ANOVAs further analyzed the effect that each individual
independent variable, cell line or hypoxia exposure, had on each gene expression level
(HIF-1α, HIF-1, and GLUT1) (Table 5). Put differently, the above studies analyzed the
general effect that each independent variable had on the entire group of dependent
variables with the MANOVA (Table 4) followed by the specific effect that each independent
variable had on each dependent variable individually using multiple univariate ANOVAs
(Table 5).
These studies were followed with analysis using a pairwise comparison model from
the univariate ANOVAs that followed the MANOVA (Tables 6-8). These analyses
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characterized the effects that all of the various time points spent using hypoxia
environment exposure treatment (0, 3, 6, 12, and 24 hours) had on the expression of each
gene of interest individually, as opposed to looking at the effects of general hypoxia without
specifying significance to any hypoxia time point. Overall, the pairwise comparison analysis
compared the expression levels of each gene after the cell lines spent various amounts of
time (0, 3, 6, 12, or 24 hours) in a hypoxic environment. Between the time zero of the assay
and 3 hours spent in hypoxia, HIF-1α expression showed a statistically significant change,
but no other significant HIF-1α expression changes were evident between any of the other
hypoxia time points or to the time zero in the assay (Table 6). Since HIF-1α expression has
been deemed acutely hypoxia dependent, it was surprising to see that the only significant
change in expression occurred in the first 3 hours spent in hypoxia. Initially, it was
expected that HIF-1α expression would be upregulated for the first 6 hours of the study.
However, the literature seems to support that HIF-1α expression peaks transiently in the
first few hours of hypoxia before being degraded (Holmquist-Mengelbier et al., 2006).
However, several other studies have found that HIF-1α stabilization and expression
tends to occur after short periods (acute) of exposure to hypoxia rather than when exposed
to hypoxia more chronically (12+ hours) (Holmquist-Mengelbier et al., 2006). This study
was not designed to determine the amount of time necessary to stabilize HIF-1α, but rather
to determine that it was expressed and whether its expression and stabilization correlated
with HIF-1, other HIFs, and GLUT1. Since HIF-1 expression appears to be more related to
acute exposure to hypoxia as opposed to chronic exposure (Holmquist-Mengelbier et al.,
2006), it was not surprising that HIF-1 expression was not expressed at significant levels
between all of the other time points spent in a hypoxic environment in this study (Table 6).
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As described above, pairwise comparison analyses of HIF-1 expression levels
between each of the time points in the hypoxia exposure assay. Between time zero of the
assay and six hours in hypoxia (p = .005), the expression of HIF-1 changed in a statistically
significant manner. Other significant HIF-1 expression changes occurred between time
zero and 12 hours in hypoxia (p = .002) as well as between 12 hours and 24 hours (p =
.037) in a hypoxic environment (Table 7). Since HIF-1 is the binding partner for HIF-1α,
although it is allegedly constitutively expressed, it would be assumed that the expression of
the two binding partners would coordinate with one another. HIF-1 downstream signaling
could depend on the amount of HIF-1 present. It was expected that HIF-1 expression
would be stable this study and that HIF-1α would be variable and it was thought to display
its hypoxia responsive downstream signaling within the first three hours of HIF-1α being
stabilized, as HIF-1α has been said to mediate an acute response in hypoxia whereas HIF2α supposedly mediates downstream signaling in a more chronic response in a hypoxic
environment. Some reports claim that HIF-1 binds to alpha subunits of other HIF
isoforms, most notably HIF-2α.
The pairwise comparison then measured the expression changes of GLUT1 (Table 8
and Figure 16), which was more widely affected by time spent in a hypoxic environment
than HIF-1α or HIF-1. Statistically significant changes in GLUT1 expression were evident
between the following hypoxia time points: 0-3 hours in hypoxia (p = .000), 0-6 hours in
hypoxia (p = .000), 0-12 hours in hypoxia (p = .001), 0-24 hours in hypoxia (p = .000).
There have been reports that both HIF-1 and HIF-2 expression modulate glucose
metabolism and have been shown to upregulate genes involved with metabolism, notably
GLUT1 and GLUT3. As reported above in this study, HIF-1α and HIF-2α expression changes
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occur after differing lengths of time spent in a hypoxic environment, which could mean that
GLUT1 expression is being constantly upregulated due regardless of which HIF is
upregulated at the time, since both HIFs 1 and 2 have been implicated with GLUT-1
upregulation.
Next, pairwise comparisons were conducted to analyze the effects of cell line on the
expression of each gene. Shown in Table 9, HIF-1α expression was significantly different in
U87MG versus MSU1.1 cells, which was expected, but the MSU1.1 line has not been well
characterized to this point making this finding potentially novel. Most notably is that HIF1α expression can be upregulated by oncogenic signaling, which is typical in cancerous
cells but not in healthy cells, which in this study are represented by the MSU1.1 cell line.
Additionally, aberrant signaling can mimic hypoxic conditions by initiating the expression
of HIF downstream genes, but while bypassing HIF. This is likely true with the expression
of vascular endothelial growth factor, VEGF. Aberrant signaling of many genes can initiate
hypoxic conditions and the subsequent expression of HIF-1α, which can account for why
there are significantly different expression levels based on the cell line they are expressed
in (U87MG cancer cells versus MSU1.1 fibroblast cells). The HIF-1 expression changes
were not significantly resulting from the cell line it was expressed in. Not surprisingly, the
expression of GLUT1 was significantly tied to the cell line. It is well documented that
GLUT1 expression is typical in normal tissue and is overexpressed in cancerous tissues.
Knowing this, it is not surprising that GLUT1 expression is significantly elevated in the
cancer cell line U87MG as opposed to the ‘normal’ MSU1.1 cells used in this study.
However, after conducting EP-PCR, this study only encompassed two cell lines (MSU1.1
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fibroblasts and U87MG cancer cells) for the qPCR aspects. Therefore, subsequent studies
are needed to confirm and expand on this study.
The estimated marginal means were calculated using all of the variables in the
study: cell line, hypoxia time points, shown in the context of changes in expression of the
genes of interest in this study (Table 10). Additionally, the means calculated in Table 10
comprise the data points for Figures 14-16. In Figure 14, HIF- 1α expression was
significantly correlated (p = .001) to the cell line in which it was expressed (U87MG versus
MSU1.1). Surprisingly, as discussed above with Table 5, there were no significant HIF- 1α
expression changes evident after hypoxia exposure, except in the first three hours in a
hypoxic culture environment (p = .215). Additionally, the combined effects of cell line and
hypoxic environment treatment did not elicit any statistically significant changes in HIF- 1α
expression (p = .558) (Table 5). The estimated marginal means of the effects of cell line,
hypoxic exposure, and the combined effects on HIF-1 expression were analyzed in Table
10 and then visualized in Figure 15. HIF-1 was not significantly affected by the IV cell line
(p = .911) but was surprisingly correlated with time spent in a hypoxic environment (p =
.018). The combined effects of both cell line and hypoxic exposure did not lead to
significant changes in HIF-1 expression (p = .332) (Table 10 and Figure 15). Overall,
hypoxic exposure was the only variable that affected HIF-1 expression in this study, which
was surprising and will be discussed more in depth in the following chapter. The estimated
marginal means of GLUT1 expression were also depicted in Table 10 and visualized in
Figure 16. GLUT1 expression correlated to the cell line it was expressed in (p = .000) and
was also significantly affected by the hypoxic treatment (p = .000) and when combined

58

effects of cell line and hypoxia treatment (p = .002). The significance of GLUT1 expression
changes in reference to hypoxia and cell line will be discussed in the following section.
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800 bp
350 bp
300 bp
250 bp
200 bp
150 bp
100 bp
50 bp

98 bp

HIF-1ɑ

55 bp

HIF-1β Set 1

80 bp

HIF-1β Set 2

FIGURE 6: EXPRESSION OF THE GENES HIF-1 AND HIF-1 WAS CONFIRMED IN BOTH HYPOXIA
TREATED U87MG CELLS AS WELL AS IN U87MG CELLS THAT ONLY GREW IN A NORMOXIC
ENVIRONMENT .
From left to right: 50 bp DNA ladder, HIF-1 (98 bp) after hypoxic exposure (treatment),
HIF-1 (98 bp) expression after no hypoxic exposure (control), blank lane, HIF-1 (55 bp)
expression after hypoxic environment exposure (treatment), HIF-1 (55 bp) expression
after no hypoxic environment exposure (control), blank lane, HIF-1 (2nd primer set- 80
bp) expression after hypoxic environment exposure (treatment), HIF-1 (2nd primer set80 bp) expression in normoxia- after no hypoxic environment exposure (control), blank
well.
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800 bp
350 bp
300 bp
250 bp
200 bp
150 bp
100 bp
50 bp

98 bp

HIF-1ɑ

55 bp

HIF-1β Set 1

80 bp

HIF-1β Set 2

FIGURE 7: EXPRESSION OF THE GENES HIF-2A AND HIF-2B WAS CONFIRMED IN BOTH HYPOXIA
TREATED U87MG CELLS AS WELL AS IN U87MG CELLS THAT ONLY GREW IN A NORMOXIC
ENVIRONMENT . HIF-3 A WAS NEITHER CONFIRMED TO BE EXPRESSED IN HYPOXIA TREATED
U87MG CELLS NOR IN CONTROL NORMOXIA TREATED U87MG CELLS.
From left to right: 50 bp DNA ladder, HIF-2 (183 bp) after hypoxic exposure (treatment),
HIF-2 (183 bp)expression after no hypoxic exposure (control), blank lane, HIF-2 (234
bp) expression after hypoxic environment exposure (treatment), HIF-2 (234 bp)
expression after no hypoxic environment exposure (control), blank lane, HIF-3 (1st
primer set) (72 bp)expression after hypoxic environment exposure (treatment), HIF-3
(1st primer set) (72 bp) expression after no hypoxic environment exposure (control), blank
well.
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-

70 bp
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50 bp

231 bp
177 bp

HIF-3a
Primer
Set 2

HIF-3B

GLUT1

FIGURE 8: EXPRESSION OF THE GENES HIF-3 AND GLUT1 WAS CONFIRMED IN BOTH HYPOXIA
TREATED U87MG CELLS AS WELL AS IN U87MG CELLS THAT ONLY GREW IN A NORMOXIC
ENVIRONMENT . T HE SECOND PRIMER SET DESIGNED FOR HIF-3 NEITHER CONFIRMED HIF-3
EXPRESSION IN HYPOXIA TREATED U87MG CELLS NOR IN CONTROL NORMOXIA TREATED U87MG
CELLS .
From left to right: 50 bp DNA ladder, HIF-3 (2nd primer set) (70 bp) after hypoxic
exposure (treatment), HIF-3 (2nd primer set)(70 bp) expression after no hypoxic
exposure (control), blank lane, HIF-3 (177 bp) expression after hypoxic environment
exposure (treatment), HIF-3 (177 bp) expression after no hypoxic environment exposure
(control), blank lane, GLUT1 (231 bp) expression after hypoxic environment exposure
(treatment), GLUT1 (231 bp) expression after no hypoxic environment exposure (control),
blank well.
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GLUT3
FIGURE 9: EXPRESSION OF GLUT3 WAS CONFIRMED IN BOTH HYPOXIA TREATED U87MG CELLS
AS WELL AS IN CONTROL (N ORMOXIA) U87MG CELLS .
From left to right: 50 bp DNA ladder, GLUT3 (75 bp) after hypoxic exposure (treatment),
GLUT3 (75 bp) in U87MG cells only exposed to normal oxygen conditions (control).
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FIGURE 10: EXPRESSION OF HIF-1, HIF-1, HIF-2, HIF-2, HIF-3, AND GLUT1 IN
MSU1.1 FIBROBLAST CELLS AFTER 48 HOURS OF HYPOXIA EXPOSURE .
F ROM L EFT TO RIGHT : 50 BP DNA LADDER, CONTROL LANE WITH NO TEMPLATE MSU1.1 CDNA,
HIF-1 (98 BP ), HIF-2 (183 BP), HIF-2 (234 BP ), HIF-3 (177 BP), AND GLUT1 (231 BP ).
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T ABLE 3: SUMMARY OF END-POINT PCR STUDY
THE FOLLOWING TABLE DEPICTS THE RESULTS OF THE END-POINT PCR AND SUBSEQUENT GEL
ELECTROPHORESIS OF THE GENES IN U87MG AND MSU1.1 CELLS : HIF-1Α, HIF-1 (1ST AND 2ND
P RIMER P AIR S ETS), HIF-2Α, HIF-2, HIF-3Α (1ST AND 2ND PRIMER PAIR S ETS), HIF-3,
GLUT1, AND GLUT3.

Summary of End-Point PCR Study
Genes Tested
HIF-1a
HIF-1b
HIF-2a
HIF-2b
HIF-3a- 1st Primer Set
HIF-3a- 2nd Primer Set
HIF-3b
GLUT1
GLUT3

U87 Glioblastoma Cells
Normoxia
Hypoxia
Present
Present
Present
Present
Present
Present
Present
Present
Inconclusive
Inconclusive
Inconclusive
Inconclusive
Present
Present
Present
Present
Present
Present
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MSU1.1 Fibroblast Cells (Control Cells)
Normoxia
Hypoxia
Present
Present
Not Tested
Not Tested
Present
Present
Present
Present
Not Tested
Not Tested
Not Tested
Not Tested
Present
Present
Present
Present
Present
Present

FIGURE 11: RELATIVE EXPRESSION
HYPOXIA T REATMENT.

OF

HIF-1

IN

U87MG

CELLS AND

MSU1.1 CELLS AFTER

Relative expression level of HIF-1 had a statistically significant peak in the first 3 hours of
hypoxic exposure treatment. The qRT-PCR results appear to show a trend in U87MG cells:
HIF-1α levels increase over time in hypoxia and have a significant peak after 12 hours of
hypoxia exposure. However, the trend showing a gradual increase over time, with a peak at
12 hours that is not statistically significant. The expression levels in MSU1.1 cells are
generally higher than in U87MG cells, but there is no trend in relation to time spent in
hypoxia.
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H IF -1 b F o ld C h a n g e

Relative Expression of HIF-1β After
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FIGURE 12: RELATIVE EXPRESSION OF HIF-1 IN U87MG CELLS AND MSU1.1 CELLS AFTER
HYPOXIA T REATMENT.
Two-way ANOVA was utilized for analysis of the relative fold change observed in both
U87MG and MSU1.1 cells during a hypoxia time course assay. qRT-PCR was conducted on
cDNA from RNA isolated from U87MG cells and MSU1.1 cells. In U87MG cells, HIF-1 levels
increase over time in hypoxia and peak at 12 hours, but the trend is not statistically
significant. No distinct trend is apparent in MSU1.1 cells. There was a distinctly higher
baseline expression of HIF-1 seen in MSU1.1 cells than in the other genes investigated in
this study: HIF-1a in Figure 11 and GLUT1 in Figure 13.
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FIGURE 13: RELATIVE EXPRESSION OF GLUT1 IN U87MG AND MSU1.1 CELLS AFTER HYPOXIA
T REATMENT .
qRT-PCR results appear to show a trend in U87MG cells: GLUT1 levels increased over time
spent in hypoxia and peaked at 24 hours. Using MANOVA pairwise comparisons, the mRNA
fold change levels of in U87MG and MUS1.1, that were measured at each hypoxia time point
(3,6,12, and 24 hours), were normalized to the baseline GLUT1 mRNA expression from
U87MG and MSU1.1 cells that were never exposed to hypoxic conditions.
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TABLE 4: ∆CT VALUES USED FOR MANOVA MULTIVARIATE ANALYSIS

The following chart depicts the ∆CT values determined by the StepOnePlus Thermocycler
software. The following values were utilized for MANOVA analysis. The ∆CT was utilized
over the ∆∆CT to keep the normoxia ∆Ct values to use as a control factor in the MANOVA
analysis. The MANOVA results are shown in Table 4.
Raw Data used for MANOVA Multivariate Analysis
Cell Line

U87

MSU1.1

Treatment

Δ CT HIF1a

Δ CT HIF1b

Δ CT GLUT1

Normoxia

0.390237808

8.862180233

6.975073179

Normoxia

4.681705793

11.33155982

11.833498

Normoxia

4.256052971

10.21491146

12.66498693

3 Hour

0.959792773

10.76535384

8.108195623

3 Hour

3.697454453

9.111228943

8.134410222

3 Hour

3.657238324

9.22144858

10.88333511

6 Hour

-1.579455058

7.83086268

8.561536789

6 Hour

4.533393542

7.603870074

7.842486064

6 Hour

4.254323324

8.735117594

11.44408894

12 Hour

0.86288929

7.628475507

7.218052864

12 Hour

0.994344076

6.518761953

6.66847229

12 Hour

2.983535767

7.028027217

11.17832947

24 Hour

0.192746798

8.476341565

0.073177338

24 Hour

5.204382261

10.5066309

6.624696732

24 Hour

4.931388855

8.970122019

9.319644292

Normoxia

3.142354965

8.140199025

5.464523315

Normoxia

5.871913433

10.85678816

11.15261587

Normoxia

4.286186854

10.8575236

10.87225914

3 Hour

2.596813202

8.067699432

4.847998301

3 Hour

2.570558548

7.713668823

9.600447973

3 Hour

3.153512319

9.428974152

7.063512166

6 Hour

2.392367045

7.469454447

5.085081418

6 Hour

3.588159243

9.148351351

8.939088821

6 Hour

4.331070582

8.967363993

9.863989512

12 Hour

3.747689565

8.277808507

4.958525976

12 Hour

3.419293086

8.271207809

9.395822525

12 Hour

1.733569463

8.984543482

10.72193146

24 Hour

3.216023127

8.594952901

4.716258367

24 Hour

3.787295659

8.864278793

9.2711188

24 Hour

5.77850914

10.09346962

8.524061203
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T ABLE 5: MANOVA TESTS OF BETWEEN -SUBJECTS EFFECTS
The MANOVA was utilized the analyze the general effect that each independent variable
had on the group of dependent variables: HIF-1α, HIF-1, and GLUT1. However, the
MANOVA analyzed the effects that these independent variables (cell line and hypoxia
treatment) had on the dependent variables clumped as a group of genes. Significant effects
were using all four of the multivariate statistical analyses: Pillai’s Trace, Wilks’s Lambda,
Hotelling’s Trace, and Roy’s Largest Root. P-values were all less than 0.05, which indicates
a strongly significant effect resulting from the independent variables labeled in the first
column of the table.
*Statistically significant values are highlighted in the figure below.
MANOVA Test of Between Subjects Effects
Effect
Pillai's Trace
Intercept

CellLine

Treatment

Cell Line *
Treatment

Value

F

Hypothesis
df

Error df

Sig.

Noncent.
Parameter

Observed
Powerd

0.994

975.499b

3.000

17.000

0.000

2926.498

1.000

Wilks' Lambda

0.006

975.499b

3.000

17.000

0.000

2926.498

1.000

Hotelling's Trace

172.147

975.499b

3.000

17.000

0.000

2926.498

1.000

Roy's Largest Root

172.147

975.499b

3.000

17.000

0.000

2926.498

1.000

Pillai's Trace

0.845

30.849b

3.000

17.000

0.000

92.546

1.000

Wilks' Lambda

0.155

30.849b

3.000

17.000

0.000

92.546

1.000

Hotelling's Trace

5.444

30.849b

3.000

17.000

0.000

92.546

1.000

Roy's Largest Root

5.444

30.849b

3.000

17.000

0.000

92.546

1.000

Pillai's Trace

1.220

3.256

12.000

57.000

0.001

39.069

0.987

Wilks' Lambda

0.154

3.872

12.000

45.269

0.000

39.124

0.982

Hotelling's Trace

3.219

4.203

12.000

47.000

0.000

50.439

0.998

Roy's Largest Root

2.363

11.227c

4.000

19.000

0.000

44.906

0.999

Pillai's Trace

1.021

2.449

12.000

57.000

0.012

29.390

0.938

Wilks' Lambda

0.218

2.939

12.000

45.269

0.004

29.974

0.932

Hotelling's Trace

2.570

3.355

12.000

47.000

0.001

40.262

0.986

Roy's Largest Root

2.143

10.178c

4.000

19.000

0.000

40.710

0.998

a. Design: Intercept + Cell Line + Treatment + Cell Line * Treatment
b. Exact statistic
c. The statistic is an upper bound on F that yields a lower bound on the significance level.
d. Computed using alpha = .05
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T ABLE 6: T EST OF BETWEEN -SUBJECTS EFFECTS SHOWN FOR E ACH GENE OF INTEREST
Univariate ANOVAs were performed after the MANOVA to determine whether the
independent variables (cell line, in-vitro hypoxic exposure, and the combined effects from
the two variables) influenced the expression of the each of the dependent variables (HIF1α, HIF-1, and GLUT1), when viewed autonomously from the other genes. The univariate
tests concluded that cell line had a significant effect on the individual expression levels of
HIF-1α (p = .001) and GLUT1 (p = .000), but not on HIF-1. In-vitro hypoxia exposure had a
significant effect on the individual expression of HIF-1 (p = .018) and GLUT1 (p =.000) and
surprisingly not on HIF-1α (p = .215), which is surprising since it is considered mainstream
that HIF-1 α is successfully activated by a hypoxic environment. Then the effects of both
independent variables were combined to determine their mutual effect on each gene’s
expression level; when combined these two factors had a significant effect on GLUT1
expression (p = .002).
*Statistically significant values are bolded in the figure below.
Tests of Between-Subjects Effects
Type II Sum
of Squares

df

Mean
Square

F

Sig.

Noncent.
Parameter

Observed
Power

HIF1a Log

3.480a

9

0.387

2.618

0.037

23.565

0.803

HIF1b Log

1.734b

9

0.193

2.272

0.063

20.452

0.733

GLUT1 Log

75.899c

9

8.433

13.708

0.000

123.375

1.000

HIF1a Log

19.375

1

19.375

131.204

0.000

131.204

1.000

HIF1b Log

211.273

1

211.273

2491.413

0.000

2491.413

1.000

GLUT1 Log

50.621

1

50.621

82.285

0.000

82.285

1.000

HIF1a Log

2.140

1

2.140

14.495

0.001*

14.495

0.950

HIF1b Log

0.001

1

0.001

0.013

0.911

0.013

0.051

GLUT1 Log

37.322

1

37.322

60.668

0.000*

60.668

1.000

HIF1a Log

0.947

4

0.237

1.603

0.215

6.410

0.399

HIF1b Log

1.311

4

0.328

3.864

0.018*

15.454

0.805

GLUT1 Log

23.540

4

5.885

9.566

0.000*

38.264

0.997

HIF1a Log

0.455

4

0.114

0.770

0.558

3.081

0.202

HIF1b Log

0.417

4

0.104

1.228

0.332

4.913

0.310

GLUT1 Log

14.993

4

3.748

6.093

0.002*

24.371

0.954

HIF1a Log

2.806

19

0.148

Source

Corrected Model

Intercept

Cell Line

Treatment

CellLine *
Treatment

Error

Total

Corrected Total

HIF1b Log

1.611

19

0.085

GLUT1 Log

11.689

19

0.615

HIF1a Log

25.660

29

HIF1b Log

214.618

29

GLUT1 Log

138.208

29

HIF1a Log

6.285

28

HIF1b Log

3.346

28

GLUT1 Log

87.587

28

a. R Squared = .554 (Adjusted R Squared = .342)
b. R Squared = .518 (Adjusted R Squared = .290)
c. R Squared = .867 (Adjusted R Squared = .803)
d. Computed using alpha = .05
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T ABLE 7: PAIRWISE COMPARISONS OF VARIOUS TIME POINTS IN HYPOXIC ENVIRONMENT AND
EFFECTS SEEN IN THE EXPRESSION OF HIF-1 Α CONDUCTED BY MULTIPLE UNIVARIATE ANOVA .
The following table depicts the results of multiple univariate ANOVAs that were conducted
to determine the effects that each hypoxia exposure time point had on the expression of
HIF-1α. This chart does not include any effects from cell line, only the effects of hypoxia
exposure treatment. Between 0-3 hours of hypoxia, there was a significant change in the
relative expression of HIF-1α.
*Statistically significant values are highlighted and bolded in the figure below.
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T ABLE 8: PAIRWISE COMPARISONS OF THE EXPRESSION LEVELS OF HIF -1 AT EACH HYPOXIA TIME
POINT CONDUCTED BY MULTIPLE UNIVARIATE ANOVA ANALYSIS

The following table depicts the effects that the hypoxia exposure time point had on the
expression of HIF-1. This chart does not include any effects from cell line, only the effects
resulting from hypoxic exposure treatment. Between the following time periods there were
significant changes in the expression of HIF-1: 0-6 hours, 0-12 hours, 12-24 hours in
hypoxia.
*Statistically significant values are highlighted and bolded in the figure below.

73

T ABLE 9: MULTIVARIATE ANALYSIS PAIRWISE COMPARISONS OF THE EXPRESSION LEVELS OF
GLUT 1 AT EACH HYPOXIA TIME POINT CONDUCTED BY MULTIPLE UNIVARIATE ANOVA
The following table depicts the effects that the hypoxia exposure time point had on the
expression of GLUT1. This chart does not include any effects from cell line, only the effects
resulting from hypoxic exposure treatment. Between the following time periods there were
significant changes in the expression of GLUT1: 0-3 hours, 0-6 hours, 0-12 hours, and 0-24
hours in hypoxia.
*Statistically significant values are highlighted in the figure below.
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T ABLE 10: M ULTIPLE UNIVARIATE ANOVA PAIRWISE COMPARISONS OF EXPRESSION LEVELS OF
HIF-1, HIF-1 AND GLUT 1 IN U87MG CELLS AND MSU 1.1 CELL LINES .
The following table depicts the significance of the effects seen in the individual gene
expression levels of HIF-1α, HIF-1, and GLUT1. Each gene was analyzed separately along
with a concordant independent variable, cell line. Below it shows that HIF-1α expression is
significantly different in the two cell lines and it is visualized in Figures 11 and 14. In this
analysis, HIF-1 expression was not significantly affected by cell line, which was also found
in the multiple univariate ANOVAs depicted in Table 5. GLUT1 expression was significantly
affected by the cell line it was being expressed in, which was also shown in Table 5.
*Statistically significant values are highlighted in the figure below.
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T ABLE 11: ESTIMATED MARGINAL MEANS OF HIF-1Α, HIF-1, AND GLUT1 IN BOTH U87MG
AND MSU1.1 CELL LINES
The following table shows the estimated marginal means of the measured effects that each
cell line and hypoxia time point have on the gene being expressed (HIF-1α, HIF-1, and
GLUT1). These values are visualized in Figures 14-16 and their significance is discussed
above in the results section.
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FIGURE 14: M ULTIVARIATE ANALYSIS E STIMATED M ARGINAL MEANS PLOT DEPICTING HOW CELL
LINE IS SIGNIFICANTLY CORRELATED TO HIF-1 A RELATIVE EXPRESSION LEVEL CHANGES .
This chart illustrates the statistical analysis data shown in Table 10. Overall, HIF-1
expression was significantly correlated to the cell line it was expressed in: U87MG versus
MSU1.1 (p = .001). However, the hypoxia treatment did not lead to significant changes in
HIF-1 expression (p = .215) and there was no significance when the effects of cell line and
hypoxia treatment were combined during statistical analysis (p = .558).
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FIGURE 15: M ULTIVARIATE ANALYSIS E STIMATED M ARGINAL MEANS PLOT DEPICTING HOW
HYPOXIA EXPOSURE OVER TIME LEADS TO HIF-1 B RELATIVE EXPRESSION LEVEL CHANGES IN BOTH
U87MG CELLS AND MSU1.1 CELLS.
This chart illustrates the data shown in Table 10. Overall, HIF-1 expression was not
significantly correlated to the cell line it was expressed in: U87MG versus MSU1.1 (p =
.911). However, HIF-1 expression was significantly correlated with hypoxia treatment (p
= .018). When the effects of cell line and hypoxia treatment were combined during
statistical analysis, the interaction was not significant (p = .332). Overall, hypoxia treatment
significantly affected HIF-1 expression.
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FIGURE 16: M ULTIVARIATE ANALYSIS E STIMATED M ARGINAL MEANS PLOT DEPICTING HOW
HYPOXIA EXPOSURE OVER TIME LEADS TO GLUT1 RELATIVE EXPRESSION LEVEL CHANGES .
This chart illustrates the data shown in Table 10. Overall, GLUT1 expression was
significantly correlated to the cell line it was expressed in: U87MG versus MSU1.1 (p =
.000). GLUT1 was also significantly correlated with hypoxia treatment (p = .000). When the
interacting effects of cell line and hypoxia treatment were combined during statistical
analysis, the interaction was also significant (p = .002).
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Discussion

The aim of this study was to determine whether hypoxia has a role in regulating the
expression of HIF-1, HIF-1, and GLUT1 in a GBM cancer cell line. We hypothesized that
the expression of these genes is proportional to in-vitro hypoxic conditions. The in-vitro
model consisted of the U87MG (GBM) cell line as well as MSU1.1 (fibroblast) cell line and
relative gene expressions of HIF-1, HIF-1, and GLUT1 were characterized in these lines.
Although MSU1.1 cells were used as a control and therefore not the focal point of the study,
the limited number of studies characterizing MSU1.1 cells make findings from this study
potentially novel. Contrastingly, the expressions of HIF-1, HIF-1, and GLUT1 as well as
the direct relationship that HIF-1 and HIF-1 expression have on downstream targets
such as GLUT1, have been well characterized in many studies. However, the relationship of
acute versus chronic hypoxia on the expression of these genes has not been fully
elucidated.
There appear to be two factors modulating HIF differential regulation: the severity
of the hypoxic environment and time spent in hypoxia (acute versus chronic). It appears
that HIF-1 expression is more responsive to severe hypoxia (1-3% O2) than the other HIF
proteins, primarily HIF-2, whose expression has been characterized in less hypoxic
conditions (5% O2) (Holmquist-Mengelbier et al., 2006). Additionally, it has been
postulated that HIF-2 rather than HIF-1 mediates responses to chronic hypoxia (12+
hours), while HIF-1 only mediates responses to acute episodes of hypoxia. In two
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neuroblastoma cell lines grown in 1% O2, expression of HIF-1 climbed rapidly in the first
couple of hours in hypoxia, but then gradually decreased after 72 hours. Contrastingly,
HIF-2 protein expression consistently climbed in 1% O2 for all 72 hours of the study.
When taken together it suggests that HIF-2 and not HIF-1 is likely responsible for
changes in chronically hypoxic areas at physiological O2 levels, at least in a neuroblastoma
model (Holmquist-Mengelbier et al., 2006).
It is worth noting that in the aforementioned neuroblastoma model, HIF-2 mRNA
levels increased in both 1% and 5% O2 conditions despite a concurrent rise in PHD2 and
PHD3 protein levels, whose role is to inactivate HIFs. This data suggests that HIF-2 grows
less sensitive to PHDs over time or that high protein synthesis of HIF-2 can counteract
PHD degradation (Holmquist-Mengelbier et al., 2006). With this study in mind, it is a good
reminder that any relative expression changes noted in this study could be due to a
decreased sensitivity to other protein regulators rather than simply being upregulated.
Acute versus chronic hypoxia in the context of HIF-1 versus HIF-2 expression was not
investigated in this study, aside from the confirmed presence of HIF-2, HIF-2, and HIF-3
were confirmed in U87MG and MSU1.1 cells in both normoxia and hypoxia using end-point
PCR. Further studies investigating the relative expression levels of the various HIFs in
various tissues needs to be done. A particularly underdeveloped area of HIF research is
regarding the temporal differences of the HIFs as well as their general sensitivity to O2
conditions (Holmquist-Mengelbier et al., 2006) in the tumor microenvironment and in
normal tissues. However, studies on the genes downstream of HIFs, such as GLUT1, are
needed to understand the GBM microenvironment at the various proximities to
vasculature.
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This study aimed to confirm that HIF-1, HIF-1, and GLUT1 are all expressed in
U87MG cells, using the largely uncharacterized MSU1.1 fibroblast cells as a ‘novel’ control
cell line. The expression of HIF-1, HIF-1, HIF-2, HIF-2, HIF-3, GLUT1, and GLUT3
were confirmed in U87MG and MSU1.1 cells (Figures 6-10). However, the presence of HIF3 in either cell line was not successfully characterized in this study, very likely due to
primer design issues. It is possible that the primer could be effective, but that the
conditions needed to induce expression of HIF-3 might not have been ideal in the design
of this study. However, that is unlikely since ‘moderate’ hypoxia has been shown to induce
the expression of some HIF-3 variants (Heidbreder et al., 2003). To test this in an in-vitro
model, cells could be exposed to 1% and 5% O2 levels for time periods spanning a few
minutes to 72 hours could elucidate more about HIF-3 relative expression.
The NCBI Gene Database and Blast were utilized to design the primers and used to
test the sequences of HIF-3 primers that were used in past studies. Upon researching, it
was discovered that many of the published HIF-3 primer sequences did not successfully
target HIF-3 when analyzed. Therefore, the characterization of HIF-3 published thus far
might be more inconclusive than thought prior to this study. Due to the issues designing a
suitable HIF-3 primer in this study and or its lack of expression and amplification, its
characterization was not continued after the EP-PCR phase of this study. However, it
remains a highly contentious aspect of hypoxia medicated expression changes in GBM.

82

General Effects of Cell Line and Hypoxic Exposure Treatment on
Lumped Expression of HIF -1, HIF-1 , and GLUT1

The qPCR data acquired only investigated the expression of HIF-1, HIF-1, and
GLUT1. As mentioned previously, (p. 43, 49-50), two types of statistical analyses were
conducted: MANOVA and multiple Two-way ANOVAs. MANOVA was conducted to
determine the general effect that each independent variable (IV) or the interaction of the
two IVs (Cell line and hypoxia exposure), had on the expression of all the following genes
lumped together: HIF-1, HIF-1, and GLUT1 (Table 4). These results show that cell line,
hypoxic exposure, and the interaction of the two factors each independently led to
significant general effects in the expression of the group of target genes (HIF-1, HIF-1,
and GLUT1) and are shown in Table 4. Since a general effect from the cell lines and hypoxic
treatment had significant effects in gene expression, additional statistical tests were
conducted to determine the effects that each IV had on the expression of each individual
gene of interest.
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Specific Effects of Cell Line and Hypoxic Exposure Treatment on
Gene Expression

Effect of Cell Type on Individual Genes Expressed

Multiple two-way ANOVAs identified significant correlations between cell type and
each of the following genes (DVs): HIF-1 and GLUT1. It was expected that both genes
would be upregulated in the U87MG GBM cells compared to the MSU1.1 cells since GLUT1
has been shown to be overexpressed in cancerous tissues, including GBM (Ma et al., 2015)
(J. Liu et al., 2015) (Asmaa Gaber Abdou, MD et al., 2015) (Labak et al., 2016) (Nes,
Johannes AP, et al, 2015) (Bache et al., 2015). GLUT1 is a downstream target gene of HIF-1,
but not solely of HIF-1α and is over-expressed in cancerous tissues, whether resulting from
hypoxia or oncogenic activation, or can just result from hypoxic normal tissues. In this
study, the differential expression of HIF-1α in the two cell lines was higher in GBM cells
than in the control MSU1.1 fibroblasts used in this study, which aligns with the general
knowledge of the field. The lack of effect seen in HIF-1 was surprising because of its
concordant expression with HIF-1, which is upregulated in many tissues and in malignant
tumors. Therefore, U87MG and MSU1.1 fibroblast cells likely have differential signaling of
hypoxia induced HIF-1 stability and the downstream GLUT1 upregulation. More
specifically, other HIFs could be at play in this scenario, such as HIF-2, and this requires
future study to better understand this phenomenon.
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Effect of Hypoxia Exposure Treatment on Individual Genes Expressed
Two-way ANOVA also found that hypoxia exposure treatment affected HIF-1 and
GLUT1 expression, but surprisingly not HIF-1 expression except within the first three
hours of hypoxic exposure. It was expected that GLUT1 would be responsive to relative
oxygen levels as well as to the cell line in which it was expressed. Many studies have
reported that GLUT1 is enriched in areas of the brain, especially in endothelial cells lining
the blood brain barrier. Since GLUT1 is upregulated in healthy brain tissues, it isn’t
surprising that GLUT1 is overexpressed in GBM cells since they occur in the brain. This
upregulation of GLUT1 seen is adaptive in light of the Warburg Effect. Studies have shown
that cancer cells display a tendency to metabolize glucose more than normal cells. Cancer
cells perform aerobic glycolysis as their main method of ATP generation rather than using
mitochondrial respiration.
It was expected that HIF-1α would be responsive to hypoxia treatment in the first
few hours of the assay, which was seen in this study in the first three hours of hypoxic
exposure (G. L. Wang, Jiang, Rue, & Semenza, 1995). HIF-1 expression has been shown to
be dependent on relative oxygen concentration, but there are some reports that HIF-1 is
only present by acute hypoxia which could explain why it was overexpressed in the first
three hours as opposed to after 24 hours of hypoxic exposure. As discussed, the PHD
enzymes that regulate HIF stability are not active during hypoxia, but eventually stabilize in
chronic hypoxia and then start to again degrade HIF-1 proteins quickly as they do in
normoxia. However, if this post-translational HIF-1 protein degradation is occurring, it is
possible that HIF-2 protein might be elevated in the (5% O2) experimental conditions of
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this study, but the expression of HIF-2 likely wouldn’t have been activated until the
relative oxygen was decreased further to around 3% O2. Regardless, it does not account for
why the transcription of HIF-1 is only increased within the first three hours of hypoxic
exposure when the above changes to HIF-1 occurred after translation.

Interaction Effect of Cell Type and Hypoxia Exposure Treatment on
Individual Genes Expressed
Analysis using two-way ANOVA found that GLUT1 expression was significantly
affected when both cell line and hypoxia exposure were used as factors (Table 4).
Specifically, hypoxic exposure led to a significant upregulation of HIF-1 (Figure 12) and
GLUT1 transcription (Figure 13) in U87MG (GBM) cells compared to control MSU1.1
fibroblast cells. These results led us to reject the null hypothesis that GLUT1 and HIF-1
expression changes are directly correlated with in-vitro hypoxic conditions because there
were significant changes seen in the genes of interest due to hypoxic exposure as well as
between cell lines. The upregulation of HIF-1 was surprising because numerous other
studies have shown that HIF-1 is constitutively made and requires the hypoxia dependent
HIF-1 subunit to elicit any changes to the cell. Without HIF-1α hetero-dimerization with
the HIF-1 subunit, there is no translocation into the nucleus and no HIF initiated genetic
changes within the host cell.
As could be expected based on the above reasoning, the combined effects of cell line
and hypoxia exposure led to a significant interactional effect in GLUT1 expression. It was
expected that GLUT1 would be responsive to relative oxygen levels as well as to the cell
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line in which it was expressed. Many studies have reported that GLUT1 is enriched in areas
of the brain, especially in endothelial cells lining the blood brain barrier (Zuchero et al.,
2016). The Warburg Effect also hypothesized that cancer cells tend to metabolize glucose
more than normal cells. Cancer cells perform aerobic glycolysis as their main method of
ATP generation rather than using mitochondrial respiration. Therefore, the upregulation of
GLUT1 in U87MG cells compared to MSU1.1 cells in this study is characteristic of typical
brain cancer cells.

Potential Effect of Chronic versus Acute Hypoxia
Perhaps the stabilization of HIF-1α is more easily accomplished in malignant cells
than in healthy cells. This could be accomplished by altering the various mechanisms by
which HIF-1α is normally degraded. As there are multiple pathways that can degrade HIFs,
it is possible that some of the hypoxia regulating signaling cascades are specific to cell type
and malignancy status, as well as to the specific level of oxygen in the tumor
microenvironment. Several studies have suggested that there are also differences in HIF
family expression levels based on the percentage of oxygen in the environment (HolmquistMengelbier et al., 2006). Some would argue that the 5% O2 used in this study wasn’t low
enough and would have recommended 1% O2 or lower to stabilize HIF-1α.
Since the longest hypoxia time point in this study was 24 hours, a larger sample size
and longer treatment times might be needed to get a comprehensive understanding of HIF1α/ expression and regulation. A larger number of biological replicates as well as more
technical replicates would help to yield a more comprehensive understanding of this
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phenomenon. Overall, this study found that HIF-1 and GLUT1 were responsive to changes
in low relative oxygen levels, and HIF-1α was not.

Summary
Hypoxia has been shown to lead to GLUT1 upregulation in various cancer types including:
endometrial (Ma et al., 2015), gastric (J. Liu et al., 2015), squamous cell carcinoma (Asmaa
Gaber Abdou, MD et al., 2015), ovarian (Labak et al., 2016), meningioma (Nes, Johannes AP,
et al, 2015), and glioblastoma (Bache et al., 2015) and has been implicated in metabolic
remodeling, which is one of the hallmarks of cancer. The positive correlation of GLUT1 and
HIF-1 with an acutely hypoxic GBM microenvironment has been described in this study in
a GBM and fibroblast cell line model. This provides further confirmation that these two
proteins are interrelated. However, this is needs to be investigated further, as the hypoxia
severity was not directly tested. Additionally, GLUT1 is also upregulated in normal tissues
including the cortex, hippocampus, and the liver after short periods (2 hours) of hypoxia
(Heidbreder et al., 2003). Its upregulation has been induced by oncogenic transformation
(C. Chen et al., 2001, p. 9519) as well as by hypoxic conditions modulated by HIF-1
expression. The presence of GLUT1 in GBMs and other tumors makes it a fair candidate for
cancer therapies, but systemic treatments targeting GLUT1 might be detrimental due to the
to its widespread distribution throughout the body, especially in the brain (Denko,
2008)(Ozbudak et al., 2008)(Airley & Mobasheri, 2007).
However, GLUT3 has been shown to be hypoxia modulated via HIF-1 as well (Y. Liu
et al., 2009a)(Rooj et al., 2016), and may be a better target for cancer therapies, as both
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GLUT1 and GLUT3 have been shown to have increased expression in the hypoxic tumor
microenvironment (Y. Liu et al., 2009a) and CSC self-renewal (Christensen et al., 2015, p.
4). By extension, the HIF-modulated tumor microenvironment selects for the intra-tumoral
CSC population which is thought to indirectly confer a myriad of selective advantages to the
tumor such as tumor aggression, resistance to treatment, tumor recurrence, and invasion
of other tissues (Labak et al., 2016). Additionally, differences in glycolytic metabolism have
been found in CSC populations (Zhou et al., 2011)(Hanahan & Weinberg, 2011) which
further supports the argument that CSCs, the GBM microenvironment, and metabolic
remodeling are interrelated. A study confirmed that GLUT3 was expressed more in highly
malignant gliomas as opposed to low-grade gliomas, and since it was the predominant
GLUT in the tumor it was a good prognostic factor for patients (Y. Liu et al., 2009a). Despite
the need to study GLUT3, its relative expression was not measured in this study due to time
and budget constraints.
The direct relationship of GLUT1 and GLUT3 and their roles in GSCs are still
debated, but they appear to be very good targets for the GSC population in the GBM(Y. Liu
et al., 2009a)(Shibuya et al., 2015). Specifically, in mice, GLUT1 was identified as a major
protein in the blood brain barrier (Zuchero et al., 2016) and as the blood brain barrier is an
obstacle to drug treatment, GLUT1 being highly expressed could help identify future
mechanisms to treat GBM and other CNS malignancies. As both GLUTs 1 and 3 have been
found within GBM (Y. Liu et al., 2009b), it seems that there is a likely correlation with
tumor grade, intra-tumor cell populations, and potentially the level of hypoxia and thus
HIF-1 versus HIF-2 regulation. Exclusively HIF-2 and not HIF-1 has been shown to
regulate Oct4 expression by binding to the Oct4 promoter depicted in a mouse embryo in-
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vivo model (Covello et al., 2006, p. 4). These studies that have found HIF-2 regulates Oct4
indicates that HIF-2 is related to the stem cell subpopulation of the GBM that has been
shown to confer treatment resistance. However, knockdown of HIF-1 expression has been
linked with abrogation in CD-133 positive GSCs, which indicates also that HIF-1 has a role
with stem cells in GBM. This finding could prove useful, as it answers another question
about which proteins modulate GSCs and consequently tumor aggression, immune
suppression, and tumor recurrence. Overall, the roles of HIF-1, HIF-2, GLUT1, and
GLUT3 are still unclear, especially in clarifying which of these proteins plays a major role in
the GSC population in glioma. It is evident that hypoxia mediates the roles of them all, at
least indirectly, and that they play roles in many of the properties that make GBM difficult
to treat and thus are important for future study.

Future Studies
Additional studies would need to be conducted to further validate the data found in this
study but confirmed our overall hypothesis: hypoxia induced changes in the genes of
interest when viewed as a group. However, when studied individually, the patterns found
in this study are somewhat different than the literature has described, necessitating an
expansion of the scope of the experimental design. Future studies should include healthy
non-cancerous control cells, GSGs, normal neural stem cells, more varied in-vitro relative
oxygen levels (<5%O2), and shorter (30 seconds) and longer time periods (24-48 hours) to
analyze the mRNA expression and protein expression of these genes. There is significant
data from this study and others warranting continued studies of the relationship between
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the HIFs and GLUT1 using an in-vitro GBM model. Although, budget and time constraints
didn’t allow for exploration into GLUT-3, HIF-2, HIF-2, HIF-3 or HIF-3 expression and
regulation, they all seem to be very interesting targets to study for future therapeutic
approaches to GBM. Specifically, future studies could determine the protein levels of the
HIFs as well as the GLUTs in a GBM model with the goal of then pursuing in-vivo studies.
Specifically, the differential regulatory roles of HIF-2 and HIF-3 in a GBM model: and
especially in the subpopulations of the GBM. HIF-2 would likely be a very interesting target
to investigate and an experimental design like used in this study could be utilized. It would
also be worth also investigating how 1% hypoxia induced regulation differs from 5%
oxygen, especially when applied to the role of CSCs in the GBM model. Additionally,
expanding this study to examine actual protein levels of these genes rather than just the
relative expression level via mRNA expression, would be very important. Since these genes
elicit functions at the protein level it is necessary to evaluate them as such.
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APPENDIX: PROTOCOLS FOR RNA ISOLATION, FIRST STRAND CDNA
SYNTHESIS AND QPCR

Methods

Direct Cell Lysis

Cells were lysed directly in the cell culture dish to prevent any reversal of possible
gene expression changes induced by the treatment conditions. As it is still contested
whether brief normoxia exposure is long enough to reverse hypoxia induced gene
expression changes, this precaution was taken. Cell cultures had the media aspirated and
were then washed with 2-3 mL of cell culture grade 1xPBS.

RNA Isolation

A mixture of the Qiagen RLT buffer and a 1:1000 -Mercaptoethanol was added to
the cell culture dish to lyse the cells. In preparation, the RLT--Mercaptoethanol aliquots
were housed in tin foil covered microcentrifuge tubes to minimize light induced
degradation. 606 L of the RLT mixture was added to each culture dish. The cells were
scraped to one side of the cell culture dish using a cell scraper. The lysate was transferred
to a QiaShredder and was centrifuged for two minutes. This was repeated until all the
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lysate had gone through the column. 606 L of 70% Ethanol was added to the lysate in the
bottom of the QiaShredder tube and was mixed well by pipetting. Of this mixture, 700 L at
a time was transferred to an RNeasy spin column and was centrifuged for 15 seconds at
8000xg. The flow through was discarded and this was repeated until all the homogenized
lysate had gone through the RNeasy spin column.

RNA Purification

700 L of the Qiagen RW1 buffer was added to the RNeasy spin column and the
column was spun for 15 seconds at 8000xg before discarding the column flow through. 500
L of Qiagen RPE was added to the column and was spun for 15 seconds at 8000xg before
discarding the flow through. An additional 500 L of the RPE buffer was added and the
column was spun down for 2 minutes at 8000xg and the flow through was discarded. The
column was transferred to a new collection tube and was spun for 1 minute at 8000xg. The
column was switch to another tube and then 10-20L of RNAse free water was added to
the column. The column rested for 1 minute and was then spun for 1 minute to elute the
RNA from the spin column. To increase the yield of RNA eluted from the column, the eluted
RNA at the bottom of the column was pipetted and added to the top of the column again to
get more RNA from the column. The 1 minute rest and spin were both repeated. The final
eluent was pipetted into a microcentrifuge tube and was immediately transferred to -80C
freezer until first strand cDNA synthesis was conducted.
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First Strand cDNA Synthesis

RNA concentration was determined using the ThermoScientific Nanodrop 2000c. The RNA
was then converted to cDNA via reverse transcription. Reverse transcription was
conducted on the isolated RNA using either the avian myeloblastosis virus reverse
transcriptase (AMV-RT) and the protocol suggested by the manufacturer (Promega, Cat #
M5108) or the ThermoFisher Maxima Reverse Transcriptase (Cat # EP0741). The Promega
protocol was utilized in reverse transcribing the RNA that was used in the End-Point PCR
experiments. The ThermoFisher Maxima Reverse Transcriptase was used to make the
cDNA for the qPCR experiments. The switch to the Maxima reverse transcriptase reagent
was done due to increased efficiency and cost reduction.

Promega AMV-Reverse Transcriptase Protocol

1.0 g of Oligo (dT)15 primer was added to 2 g of RNA in a microcentrifuge tube and the
volume of water present did not exceed 11 L. The tube was heated at 70C for 5 minutes
and were then chilled on ice for 5 minutes. The tube was briefly centrifuged in the MyFuge
12 Mini Centrifuge (Cat# 681725) to collect all the solution at the bottom of the tube.
The following components were added in the following order:
5µl AMV Reverse Transcriptase 5X Reaction Buffer (Cat# M5108)
2.5µl dNTP mix (Cat# U1511)
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AMV RT 30 units (Cat# M5108)
Nuclease-Free Water to final volume 25µl

The tube was mixed by gently flicking the tube. If needed, the tube was briefly centrifuged
again to ensure that all the solution was at the bottom of the tube. The tube was incubated
for 60 minutes at 42C. The tubes were stored at -20C for the duration of the End-Point
PCR studies.

ThermoFisher Maxima Reverse Transcriptase Protocol

All reagents were centrifuged briefly in the MyFuge (Cat# Z681725) and kept on ice for the
duration of the protocol. The following components were added to a sterile microcentrifuge tube on ice in the following order:
2 g of template RNA
1.0 L of (100 pmol) of oligo(dT)15 primers (Cat# C1101)
1.0 L of (10 mmol) dNTP Mix (Cat# U1511)
10.5 L Nuclease-free water (Cat# EP0741)

The following reaction components were then added in the following order:

4 L 5x Maxima RT Buffer (Cat# EP0741)
0.5 L Nuclease-free water (Cat# EP0741)
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*when RNAse inhibitor was not available
1.0 L Maxima Reverse Transcriptase (Cat# EP0741)

The total volume of the reaction was 20 L. The mixture was centrifuged briefly and
immediately placed in the programmed Bio-Rad T100 Thermal Cycler. The reactions
incubated for 30 minutes at 50C. The reaction was terminated by heating the tubes to
85C for 5 minutes. The cDNA product was stored in the -20C freezer for the duration of
the qPCR studies.
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